Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Of course, I have to wait to Aug. 23rd for the JCG announcement. Specialty retailers (especially footware) appear to be doing very well with Deckers beating and raising FY outlook last week.
Buy what you buy! Come on retail sector. We know you have it in you.
SKECHERS Announces Record Second Quarter Sales, Operating Income, Net Earnings and Earnings Per Share
* Net Sales of $504.9 Million
* Earnings from Operations of $58.8 Million
* Net Earnings of $40.2 Million
* Diluted Earnings Per Share of $0.82
http://www.businesswire.com/portal/site/home/permalink/?ndmViewId=news_view&newsId=20100728006714&newsLang=en
MANHATTAN BEACH, Calif.--(BUSINESS WIRE)--SKECHERS USA, Inc. (NYSE:SKX), a global leader in lifestyle footwear, today announced financial results for the second quarter ended June 30, 2010.
Second quarter 2010 net sales increased 68.9 percent to $504.9 million compared to $299.0 million in the second quarter of 2009. Earnings from operations for the second quarter of 2010 were $58.8 million compared to a loss from operations of $7.7 million in the second quarter of 2009. Net earnings for the second quarter of 2010 were $40.2 million versus a net loss of $5.9 million in the second quarter of 2009. Second quarter diluted earnings per share were $0.82 based on 49,130,000 weighted average common shares outstanding as compared to a net loss per diluted share of $0.13 based on 46,282,000 weighted average common shares outstanding.
"Our second quarter net sales of over $500 million are a first in our 18-year history. In addition, we achieved record second quarter operating income, net earnings and earnings per diluted share on the heels of a record first quarter," began David Weinberg, chief operating officer and chief financial officer. "The significant revenue growth is attributable to strong operational execution and product development and delivery across our domestic and international wholesale and retail channels, as well as via our e-commerce platform. We believe our momentum is being meaningfully supported and enhanced by our continued marketing efforts globally."
For the six months ended June 30, 2010, net sales were $997.6 million compared to net sales of $642.4 million in the first six months of 2009. Earnings from operations for the first six months were $139.8 million compared to a loss from operations of $1.6 million in the same period of 2009. Net earnings were $96.5 million, compared to net earnings of $2.3 million in the first six months of 2009. Net earnings per diluted share in the first six months of 2010 were $1.97 per share on 48,955,000 million diluted shares outstanding versus net earnings of $0.05 per share on 46,424,000 million diluted shares outstanding for the same period last year.
Gross profit for the second quarter of 2010 was $237.6 million or 47.1 percent of net sales compared to $122.6 million or 41.0 percent of net sales in the second quarter of last year. Gross profit for the first six months of 2010 was $475.1 million or 47.6 percent of net sales versus $248.0 million or 38.6 percent of net sales in the first six months of 2009.
Robert Greenberg, SKECHERS chief executive officer, commented: "We reached a new revenue milestone with our first ever quarterly net sales of over $500 million and nearly $1 billion for the first six months of 2010. This growth is a significant achievement given that the U.S. retail market has only slightly improved from last year. The combination of our strong position and product momentum has resulted in continued penetration in the footwear market and increasing demand for our SKECHERS brand both in the United States and around the world. We remain dedicated to delivering innovative men’s, women’s and kids’ product and developing new marketing campaigns to support our efforts. We are looking forward to the back-to-school season, which we believe will be our strongest yet. The product success we achieved in the United States over the past six months is beginning to spread to markets around the world, and we believe our growth will accelerate in many of these countries. We continue to develop exciting new product and had a very positive reaction to our new lines with key accounts earlier this month, giving us a glimpse of what we expect will be a strong finish to the year. We are in a very strong position in the market with a buzz that is growing from consumers and the media. We believe that 2010 marks a new phase in SKECHERS' development, and that we will continue to strategically grow -- becoming one of the most sought after performance and lifestyle brands in the world."
"SKECHERS' top-line growth, significantly increased profitability and much improved margins are the result of our consistent efforts to deliver fresh, innovative product supported by relevant marketing around the world," Mr. Weinberg added. "Our product is in high demand, inventory is clean, and our balance sheet continues to strengthen. At quarter end, our cash position was over $273 million, even though we accelerated factory payments of $64 million and made a capital contribution of $30 million to our distribution center joint venture. We broke ground during the second quarter on this new, more efficient, 1.8 million-square-foot facility in Rancho Belago, California. With a triple digit increase in backlogs and double digit retail store comps, we believe our momentum will continue."
sts66,
Post limitations can only be done by iHub Admin.
You can send a Private Message to IH Admin to find out why at:
http://investorshub.advfn.com/boards/profile.aspx?user=111041
(you don't have to be a paying member to send them a msg)
nole
I think so. I have no idea why you would have been banned. Just a thought after seeing a rival board on your message.
Just happened again -- this is the message I got when trying to post my 3rd message of the day on the XCHO board:
You have already reached the 2 post per day limit that Admin has placed on you for this board.
This ban is set to expire: indefinite
Freebie posts had been 15/day, dunno if this limitation is being applied just to me or to all freeloaders. Can you check into it for me? Thnx.
What exactly do you mean by "you have to be careful about using other board names" when posting here? Do you mean mentioning other message boards like yahoo etc.?
I've been watching ARNA too. Are you familiar with $heff's board here on iHub? If not, you would really like it. They have a ton of good DD over there on ARNA, AVNR and several other FDA plays. Here's the link:
http://investorshub.advfn.com/boards/board.aspx?board_id=9413
I like to check out Motley Fool's cap ratings if there are a few stocks I like and need a deciding vote. I have tracked many of their 5 star stocks and they tend to do well.
You may have to be careful about using other board names even if you are just re-posting your own stuff. Looks like it's back up.
I don't see that anyone is banned. Maybe it was a glitch...try it again.
wow, not me...just got back from a 4 day vacation and catching up on messages. Bans only come from iHub admin...let me see what's up.
WTF? I got banned from posting to the XCHO board! Why? Who is responsible for that decision?
Found this while reading a report on ARNA, lists various bios and ranks them by growth. Some of them I'll be looking into. Although TheStreet hates ARNA, it's up huge today on monster volume.
P.S. I just checked TheStreet's opinion of a few more of the stocks on this list, they have a HOLD on PDLI although it's earnings are dropping big time, OPK is also rated a HOLD but with a huge increase in revs, albeit with a net negative profit margin. Motley Fool Caps rating on OPK is 3 stars (not that I put too much trust into their Caps rating system).
I know what you mean about the personal attacks and stuff....the one blowhard, especially on the Yahoo board, has gone completely off the deep end...."how many follow you?", LOL....didn't realize stock picking was a popularity contest or "show of strength" or whatever you want to call it.
Great find Nole!
That's fine...it is Cobroxin related.
I'm sorry if some of your posts were deleted, but the board was getting out of control. Off topic posts are one thing, but the personal spats going on over there are driving me nuts. Sometimes I let ihub admins delete the messages to see what's accepted and what's not. On Sunday night alone we had 10 out 11 messages deleted by admin. This past week about 40% of the messages were deleted for TOS violations.
Any questionable post from now on will be deleted until things calm down. As you can see, the board is quiet when they can't call someone else an idiot. lol.
Glad you joined the discussion over here. Check out the ibox for a lot of the microcaps that I track. They are beaten up, but most are still solid value picks.
nole
Posting this here instead of XCHO board as you may consider it OT (I don't, if you agree please cut/paste to XCHO board or tell me to do it). Another Cobroxin arthritis pain competitor just bit the dust:
UPDATE 1 - NicOx says key drug rejected by FDA
Thu Jul 22, 2010 2:07am EDT
* FDA has not approved application for Naproxcinod
* Recommends further trials on the drug
* NicOx to hold talks with FDA as soon as possible
PARIS, July 22 (Reuters) - The U.S. Food and Drug Administration has rejected NicOx's (NCOX.PA) pain drug Naproxcinod, recommending further trials, the French biotechnology group said on Thursday.
NicOx, which has spent about 10 years and 100 million euros ($127.6 million) to fund the U.S. launch of its lead anti-inflammatory drug <for osteoarthritis>, said it would hold talks with the FDA as soon as possible to discuss potential next steps.
Citing a response letter, NicOx said the FDA had recommended conducting more long-term controlled studies to assess the safety of Naproxcinod on a cardiovascular and gastrointestinal level.
An FDA advisory panel had already voted against approving the drug in May, sending NicOx shares to a four-year low.
That's why I swing by JCrew once every couple weeks. Well, that has more to do with my wife liking it I guess, but that just makes it an easy double play.
SKX : SKECHERS USA, Inc. to Report Second Quarter Financial Results on Wednesday, July 28, 2010
I own a ton of SKX in my IRA and I think $34.66 is a great entry point. If they have another great quarter, we could see $45 in a few days. Their 'Shape-Ups' line has been killing it. I know my household owns about 5 pairs of Skechers...buy what you buy.
AVNR : The Value of an SPA for Avanir Pharmaceuticals
by: Sheff Station/Seeking Alpha July 22, 2010
AVNR There are only two companies that will be up for FDA approval for their products in the second half of the year that have an SPA (special protocol assessment) with the FDA. Those companies are Avanir Pharmaceuticals (AVNR) and Vivus Pharmaceuticals (VVUS).
VVUS has a PDUFA date of October 28th for Qnexa® which treats weight loss. Avanir has a PDUFA date of October 30th for Zenvia™, which treats pseudobulbar affect. Key safety and tolerability data from the Vivus, Inc. special protocol assessment (SPA) that was not evident at the recent FDA Advisory Panel meeting is present for Avanir (AVNR) into their PDUFA date. VVUS has their SPA in a crowded but profitable market of weight loss and obesity. Avanir has their market in an often under-recognized and undertreated condition of uncontrollable laughing and crying known as PBA (pseudobulbar affect).The Avanir SPA has an emphasis on safety and tolerability to go along with the efficacy data that was clearly demonstrated in the recent STAR trial.
This article will discuss what an SPA is, the value of an SPA, and why Avanir is in a unique position leading up to their approval date in the 4th quarter of this year.
What is a special protocol assessment (SPA)?
An SPA is a definitive agreement between the FDA and a company which addresses all aspects of the design and analysis of a trial before the start of it With the SPA. The FDA presents a signed agreement that states if the trial is run exactly as designated in the SPA and the results are positive, then they (the FDA) will approve the drug. This is immensely important for any company regardless of its size.
This SPA agreement can assure companies and investors that if several million dollars are invested in a late-stage trial, then the FDA will not come back and punish the company for not having the endpoints that were identified as being needed in order to conduct a successful trial for approval. A company’s compliance with the FDA’s request makes investors feel confident in that the company has done its homework and been in communication with the FDA in its efforts with the FDA to gain approval.
With regards to the two companies, analysts at Jefferies & Co. recently (July 1st) gave AVNR a buy rating and a $10 target price and a week later (July 8th) reiterated their hold on VVUS with a target price of $9 one week prior to the July 15th Advisory Panel Meeting. They recognized the safety concerns the panel would encounter for Qnexa while other analysts expected a more positive outcome. Jefferies was spot on with their analysis on VVUS, as they will be with Avanir.
While the FDA panel agreed that the Vivus product, Qnexa, has solid efficacy data, the meeting mainly focused on five safety issues. The safety issues were: the affect of Qnexa on pregnant women, the chance of cardiovascular risks, psychiatric events, cognitive events, and metabolic acidosis.
The safety concern of the FDA Advisory Panel was evident on July 15th as the panel voted 10-6 in favor of Qnexa being not approvable.
Vivus could state that the FDA’s request for long-term safety data (greater than one year) was not in the SPA, and that their agreement was that one year of safety data was enough. Vivus was met with the safety challenges by the Special Advisory Panel Members, not those that they worked with through the SPA trial design.
If the FDA wanted more long-term data, why wasn't that requested as a part of the SPA? The challenge is that the specific concerns that the FDA had with regard to the safety data such as cardiovascular issues and increases in heart rate were not adequately addressed in the SPA in from the clinical trials it seems. Most SPAs deal with only three types of protocols: 1) Animal carcinogenicity, 2) final product stability, and 3) Phase III Clinical Trials intended to support an efficacy claim.
The problem with #3 is that there was not a need to support the already demonstrated efficacy claim. What was needed was the safety and tolerability data in the agreement with the FDA in the SPA. SPAs are usually binding with the FDA but can be considered non-binding in certain situations.
The only time the binding agreement is rendered non-binding is if:
A substantial scientific issue essential to determining safety or efficacy of the drug has been identified after the testing has begun.
Public health concerns are unrecognized at the time of the protocol assessment (occur later)
Relevant data, assumptions are found to change or are false
Sponsor does not follow the clinical study protocol
Avanir looks to have a stronger and broader SPA with the FDA. They had a Phase III study and STAR trial, with FDA guidance on clinical endpoints, that covered not only efficacy but also safety and tolerability questions. These questions specifically addressed the FDA’s concerns in 2006 with regard to their approvable letter to the company. These questions focused around safety and tolerability, not efficacy.
To address these questions, the STAR trial was designed and recommended by the FDA as a single confirmatory Phase III clinical trial of Zenvia to address the concerns of the FDA. Those concerns were adequately addressed as I will discuss in future articles focusing on the efficacy and safety of the STAR trial. What was also discussed from 2nd quarter earnings call is that the review division and team within the FDA are the same ones that reviewed the previous application in 2006. They are the same reviewers, same group, in the neurology division of the FDA. Avanir has been having ongoing and active discussions with the FDA, leading up to the approval date, since 2005. These points discussed is the value of an SPA for Avanir as we move into October!
Disclosure: Author is long AVNR, ALXA
http://seekingalpha.com/article/215828-the-value-of-an-spa-for-avanir-pharmaceuticals?source=yahoo
I'm in AVNR as well until October. Also holding CRXX and ALXA right now. I think bio plays are the way to go in this market and would like to find a few more promising plays.
My China and value micro stocks are treading water.
Absolutely, doing DD on the stocks on this list is crucial. I spent some time last night looking at the top 10, didn't like what I found (not a surprise), but did find a couple that are "real" companies with drugs coming up for approval soon.
The two I'm currently focused on are OREX (#52) and ARNA (#387), both (former) competitors of VVUS, who's fat pill was just rejected by the FDA. After spending a couple hours looking at both, I'm a little confused at the price targets for both - OREX is listed as having a much high potential gain the ARNA, but on the other hand ARNA has already signed a distribution agreement for it's fat pill and owns a mfg. facility in Europe capable of ramping up to 1 billion tabs/yr.
ARNA's drug also seems to be much more safe and equally effective (if not moreso) to OREX's candidate, and ARNA is months ahead of the game, they get FDA decision pretty soon. They even got a $50 mil pre-payment from the distributor, meaning that everyone involved thinks approval is a done deal. Good article on them here:
http://www.xconomy.com/san-diego/2009/09/18/arena-obesity-drug-passes-second-trial-angling-to-market-safe-option-for-millions-of-people/?single_page=true
One note of concern for Orexigen is some minor heart complications, which is what got Qnexa nixed.
P.S. I already own AVNR (#69), a likely double, possible triple, FDA decision due on Oct 31, and POZN (#175), which has two drugs on the market paying the bills, with a real blockbuster in the waiting, their PA325 "safer aspirin". Plus a ton of XCHO, of course
It's a very intersting list and certainly one that can be used to start some good research. However, as someone in the healthcare sales industry there is a lot of DD needed here. On top of the obvious "potential" due to FDA clearance and early stage clinical trials that need to prove effective there are more imminent issues. These include, but are not limited to, healthcare reform legislation that still casts uncertainty for reimbursement new technologies, hospital budgets and more importantly the new "product review boards" that hospitals use to see if they will let doctors use certain products and surgeon acceptance and use, to name a few.
I am a big proponent of investing in the healthcare sector. I have had some hits (MDXG from .40 to 1.70 at sell) and some misses (XCHO from .28 to .18-but still holding and now averaged at .26) This is just a heads up to make sure you always do your DD and ALWAYS protect your unit.
Top U.S. Healthcare Stocks with Highest Upside Potential Updated Jul 21, 2010 from NASD100.com
http://www.nasd100.com/2010/07/top-us-healthcare-stocks-with-highest-upside-potential-updated-jul-21-2010.html
from sts66
Below are the top U.S.-listed Healthcare stocks with highest upside potential, calculated as the difference between current price and Wall Street analysts' average target price.
Ranking | Company (Ticker) | Potential Upside
1 Harbor BioSciences, Inc. (NASDAQ:HRBR) 2044.4%
2 Generex Biotechnology Corporation (NASDAQ:GNBT) 1623.1%
3 Nile Therapeutics, Inc. (NASDAQ:NLTX) 1161.8%
4 OXiGENE, Inc. (NASDAQ:OXGN) 1151.2%
5 ARYx Therapeutics, Inc. (NASDAQ:ARYX) 1075.2%
6 AspenBio Pharma, Inc. (NASDAQ:APPY) 770.8%
7 Prana Biotechnology Limited (ADR) (NASDAQ:PRAN) 515.4%
8 CombiMatrix Corporation (NASDAQ:CBMX) 483.7%
9 XOMA Limited (NASDAQ:XOMA) 433.9%
10 Interleukin Genetics, Inc (AMEX:ILI) 400.0%
11 Peregrine Pharmaceuticals (NASDAQ:PPHM) 396.0%
12 ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) 376.2%
13 PharmAthene, Inc. (AMEX:PIP) 373.0%
14 Cytokinetics, Inc. (NASDAQ:CYTK) 360.2%
15 Cardium Therapeutics Inc. (NYSE:CXM) 350.7%
16 Biodel Inc (NASDAQ:BIOD) 349.1%
17 Sunesis Pharmaceuticals, Inc. (NASDAQ:SNSS) 334.8%
18 Columbia Laboratories Inc. (NASDAQ:CBRX) 330.1%
19 DARA BioSciences, Inc. (NASDAQ:DARA) 315.6%
20 Opexa Therapeutics Inc. (NASDAQ:OPXA) 313.8%
21 Otix Global, Inc. (NASDAQ:OTIX) 289.6%
22 OncoGenex Pharmaceuticals Inc (NASDAQ:OGXI) 260.4%
23 Cyclacel Pharmaceuticals Inc. (NASDAQ:CYCC) 259.6%
24 Aastrom Biosciences, Inc. (NASDAQ:ASTM) 257.1%
25 Enzo Biochem, Inc. (NYSE:ENZ) 253.5%
26 Biolase Technology, Inc. (NASDAQ:BLTI) 250.9%
27 ADVENTRX Pharmaceuticals, Inc. (AMEX:ANX) 246.8%
28 Idera Pharmaceuticals, Inc. (NASDAQ:IDRA) 245.2%
29 Compugen Ltd. (USA) (NASDAQ:CGEN) 236.1%
30 MDRNA, Inc. (NASDAQ:MRNA) 233.3%
31 CytRx Corporation (NASDAQ:CYTR) 228.9%
32 American Caresource Holdings, Inc. (NASDAQ:ANCI) 223.7%
33 Nymox Pharmaceutical Corporation (NASDAQ:NYMX) 222.8%
34 Inovio Pharmaceuticals, Inc. (AMEX:INO) 219.7%
35 BioDelivery Sciences International, Inc. (NASDAQ:BDSI) 215.3%
36 Alpha Pro Tech, Ltd. (AMEX:APT) 214.2%
37 RXi Pharmaceuticals Corporation (NASDAQ:RXII) 212.0%
38 Dynavax Technologies Corporation (NASDAQ:DVAX) 206.1%
39 EpiCept Corporation (NASDAQ:EPCT) 206.1%
40 BioSante Pharmaceuticals, Inc. (NASDAQ:BPAX) 204.9%
41 Anthera Pharmaceuticals Inc (NASDAQ:ANTH) 203.0%
42 SuperGen, Inc. (NASDAQ:SUPG) 197.3%
43 DepoMed, Inc. (NASDAQ:DEPO) 196.9%
44 Curis, Inc. (NASDAQ:CRIS) 193.6%
45 Celldex Therapeutics, Inc. (NASDAQ:CLDX) 190.1%
46 Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) 190.1%
47 BioSpecifics Technologies Corp. (NASDAQ:BSTC) 188.0%
48 StemCells, Inc. (NASDAQ:STEM) 185.7%
49 YM BioSciences Inc. (USA) (AMEX:YMI) 185.3%
50 Somaxon Pharmaceuticals, Inc. (NASDAQ:SOMX) 185.3%
51 Poniard Pharmaceuticals, Inc. (NASDAQ:PARD) 181.4%
52 Orexigen Therapeutics, Inc. (NASDAQ:OREX) 181.0%
53 Dyax Corp. (NASDAQ:DYAX) 180.2%
54 NovaBay Pharmaceuticals, Inc. (AMEX:NBY) 177.4%
55 WorldHeart Corporation (USA) (NASDAQ:WHRT) 175.7%
56 Ligand Pharmaceuticals Inc. (NASDAQ:LGND) 175.0%
57 Tengion, Inc. (NASDAQ:TNGN) 174.2%
58 Delcath Systems, Inc. (NASDAQ:DCTH) 169.9%
59 Celsion Corporation (NASDAQ:CLSN) 169.8%
60 MediciNova, Inc. (NASDAQ:MNOV) 168.8%
61 Repligen Corporation (NASDAQ:RGEN) 166.3%
62 ISTA Pharmaceuticals, Inc. (NASDAQ:ISTA) 162.5%
63 ZIOPHARM Oncology Inc. (NASDAQ:ZIOP) 161.8%
64 Orthovita, Inc. (NASDAQ:VITA) 161.1%
65 Derma Sciences, Inc. (NASDAQ:DSCI) 159.5%
66 Neostem Inc. (AMEX:NBS) 158.6%
67 Trubion Pharmaceuticals, Inc. (NASDAQ:TRBN) 156.4%
68 Chelsea Therapeutics International Ltd. (NASDAQ:CHTP) 156.3%
69 AVANIR Pharmaceuticals (NASDAQ:AVNR) 156.2%
70 RadNet Inc. (NASDAQ:RDNT) 154.2%
71 Alexza Pharmaceuticals, Inc. (NASDAQ:ALXA) 150.0%
72 ArQule, Inc. (NASDAQ:ARQL) 145.9%
73 Cleveland BioLabs, Inc. (NASDAQ:CBLI) 145.4%
74 Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) 145.3%
75 GenVec, Inc. (NASDAQ:GNVC) 144.6%
76 China Sky One Medical, Inc. (NASDAQ:CSKI) 143.8%
77 Skilled Healthcare Group, Inc. (NYSE:SKH) 142.6%
78 Novavax, Inc. (NASDAQ:NVAX) 139.5%
79 Oculus Innovative Sciences, Inc. (NASDAQ:OCLS) 138.7%
80 Exelixis, Inc. (NASDAQ:EXEL) 138.1%
81 BioMimetic Therapeutics, Inc. (NASDAQ:BMTI) 137.4%
82 Sucampo Pharmaceuticals, Inc. (NASDAQ:SCMP) 136.7%
83 Skystar Bio-Pharmaceutical Company (NASDAQ:SKBI) 135.8%
84 Angiotech Pharmaceuticals, Inc. (USA) (NASDAQ:ANPI) 134.4%
85 Alimera Sciences Inc (NASDAQ:ALIM) 132.1%
86 Pluristem Therapeutics Inc. (NASDAQ:PSTI) 130.5%
87 Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI) 127.8%
88 Rosetta Genomics Ltd. (USA) (NASDAQ:ROSG) 127.7%
89 AdCare Health Systems, Inc. (AMEX:ADK) 127.3%
90 Adolor Corporation (NASDAQ:ADLR) 125.5%
91 Anadys Pharmaceuticals, Inc. (NASDAQ:ANDS) 125.4%
92 pSivida Corp. (NASDAQ:PSDV) 125.4%
93 Oncothyreon Inc. (NASDAQ:ONTY) 124.2%
94 Clinical Data, Inc. (NASDAQ:CLDA) 123.7%
95 AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO) 121.5%
96 EnteroMedics Inc. (NASDAQ:ETRM) 119.8%
97 Winner Medical Group, Inc (NASDAQ:WWIN) 118.8%
98 TranS1 Inc. (NASDAQ:TSON) 118.3%
99 Solta Medical Inc. (NASDAQ:SLTM) 117.7%
100 NeurogesX, Inc (NASDAQ:NGSX) 117.1%
101 Inhibitex, Inc. (NASDAQ:INHX) 116.7%
102 Raptor Pharmaceutical Corp. (NASDAQ:RPTP) 115.7%
103 Allos Therapeutics, Inc. (NASDAQ:ALTH) 115.2%
104 Addus Homecare Corporation (NASDAQ:ADUS) 114.0%
105 Rockwell Medical Technologies, Inc. (NASDAQ:RMTI) 112.1%
106 Labopharm Inc. (NASDAQ:DDSS) 112.0%
107 Inspire Pharmaceuticals, Inc. (NASDAQ:ISPH) 111.6%
108 Keryx Biopharmaceuticals (NASDAQ:KERX) 109.5%
109 Immunomedics, Inc. (NASDAQ:IMMU) 108.3%
110 Athersys, Inc. (NASDAQ:ATHX) 106.5%
111 Antares Pharma, Inc. (AMEX:AIS) 105.6%
112 China-Biotics Inc. (NASDAQ:CHBT) 104.5%
113 Threshold Pharmaceuticals, Inc. (NASDAQ:THLD) 104.1%
114 AVI BioPharma, Inc. (NASDAQ:AVII) 103.8%
115 Cardionet Inc (NASDAQ:BEAT) 102.7%
116 Sangamo Biosciences, Inc. (NASDAQ:SGMO) 101.0%
117 Cumberland Pharmaceuticals, Inc. (NASDAQ:CPIX) 99.6%
118 China Nuokang Bio-Pharmaceutical Inc. (NASDAQ:NKBP) 98.4%
119 XenoPort, Inc. (NASDAQ:XNPT) 96.9%
120 BioClinica, Inc. (NASDAQ:BIOC) 96.1%
121 SciClone Pharmaceuticals, Inc. (NASDAQ:SCLN) 95.7%
122 Cornerstone Therapeutics, Inc. (NASDAQ:CRTX) 95.5%
123 Array BioPharma Inc. (NASDAQ:ARRY) 95.1%
124 AEterna Zentaris Inc. (USA) (NASDAQ:AEZS) 93.9%
125 Amicus Therapeutics, Inc. (NASDAQ:FOLD) 93.9%
126 Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA) 93.5%
127 American Oriental Bioengineering, Inc. (NYSE:AOB) 93.1%
128 Vical Incorporated (NASDAQ:VICL) 91.7%
129 RTI Biologics Inc. (NASDAQ:RTIX) 91.3%
130 DURECT Corporation (NASDAQ:DRRX) 90.6%
131 Flamel Technologies S.A. (ADR) (NASDAQ:FLML) 89.9%
132 DUSA Pharmaceuticals, Inc. (NASDAQ:DUSA) 88.1%
133 Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) 88.0%
134 BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) 87.5%
135 MedCath Corporation (NASDAQ:MDTH) 86.7%
136 EXACT Sciences Corporation (NASDAQ:EXAS) 86.1%
137 Optimer Pharmaceuticals, Inc. (NASDAQ:OPTR) 85.7%
138 Alliance HealthCare Services, Inc. (NYSE:AIQ) 85.2%
139 Lannett Company, Inc. (AMEX:LCI) 82.6%
140 BioScrip Inc. (NASDAQ:BIOS) 81.9%
141 IntegraMed America, Inc. (NASDAQ:INMD) 81.8%
142 Concord Medical Services Holding Ltd. (NYSE:CCM) 81.4%
143 Dendreon Corporation (NASDAQ:DNDN) 80.3%
144 LeMaitre Vascular, Inc. (NASDAQ:LMAT) 79.9%
145 InterMune, Inc. (NASDAQ:ITMN) 79.5%
146 Select Medical Holdings Corporation (NYSE:SEM) 78.9%
147 Corcept Therapeutics Incorporated (NASDAQ:CORT) 77.2%
148 Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) 76.3%
149 ISIS Pharmaceuticals, Inc. (NASDAQ:ISIS) 76.0%
150 Pharmacyclics, Inc. (NASDAQ:PCYC) 74.8%
151 MannKind Corporation (NASDAQ:MNKD) 73.7%
152 Nanosphere, Inc. (NASDAQ:NSPH) 73.3%
153 Geron Corporation (NASDAQ:GERN) 71.7%
154 Protalix BioTherapeutics Inc. (AMEX:PLX) 71.2%
155 Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) 70.9%
156 Pressure BioSciences, Inc. (NASDAQ:PBIO) 70.4%
157 Emeritus Corporation (NYSE:ESC) 70.1%
158 Continucare Corporation (AMEX:CNU) 70.0%
159 ZymoGenetics, Inc. (NASDAQ:ZGEN) 70.0%
160 China Pharma Holdings, Inc. (AMEX:CPHI) 69.4%
161 Cardiovascular Systems, Inc. (NASDAQ:CSII) 69.2%
162 Affymax, Inc. (NASDAQ:AFFY) 69.1%
163 Genomic Health, Inc. (NASDAQ:GHDX) 68.1%
164 Allied Healthcare International Inc. (NASDAQ:AHCI) 68.1%
165 Nabi Biopharmaceuticals (NASDAQ:NABI) 67.9%
166 Cerus Corporation (NASDAQ:CERS) 67.8%
167 Stereotaxis, Inc. (NASDAQ:STXS) 67.6%
168 Onyx Pharmaceuticals, Inc. (NASDAQ:ONXX) 67.4%
169 Santarus, Inc. (NASDAQ:SNTS) 67.3%
170 ThermoGenesis Corp. (NASDAQ:KOOL) 66.9%
171 RehabCare Group, Inc. (NYSE:RHB) 66.4%
172 Alphatec Holdings, Inc. (NASDAQ:ATEC) 66.2%
173 Oncolytics Biotech, Inc. (USA) (NASDAQ:ONCY) 65.3%
174 Cypress Bioscience, Inc. (NASDAQ:CYPB) 65.3%
175 POZEN Inc. (NASDAQ:POZN) 65.2%
176 Transition Therapeutics Inc. (NASDAQ:TTHI) 65.0%
177 Alere, Inc. (NYSE:ALR) 64.8%
178 Cytori Therapeutics Inc. (USA) (NASDAQ:CYTX) 64.6%
179 SeraCare Life Sciences, Inc. (NASDAQ:SRLS) 64.0%
180 LHC Group, Inc. (NASDAQ:LHCG) 64.0%
181 Halozyme Therapeutics, Inc. (NASDAQ:HALO) 63.5%
182 Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA) 63.3%
183 Sequenom, Inc. (NASDAQ:SQNM) 63.2%
184 Cynosure, Inc. (NASDAQ:CYNO) 62.3%
185 CONMED Corporation (NASDAQ:CNMD) 61.6%
186 Cadence Pharmaceuticals, Inc. (NASDAQ:CADX) 61.5%
187 Matrixx Initiatives, Inc. (NASDAQ:MTXX) 61.3%
188 NPS Pharmaceuticals, Inc. (NASDAQ:NPSP) 61.2%
189 The Spectranetics Corporation (NASDAQ:SPNC) 61.1%
190 ViroPharma Incorporated (NASDAQ:VPHM) 60.8%
191 Brookdale Senior Living, Inc. (NYSE:BKD) 60.4%
192 Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) 60.4%
193 VIVUS, Inc. (NASDAQ:VVUS) 60.2%
194 Micromet Inc. (NASDAQ:MITI) 59.6%
195 Syneron Medical Ltd. (NASDAQ:ELOS) 59.6%
196 China Biologic Products Inc (NASDAQ:CBPO) 59.2%
197 Conceptus, Inc. (NASDAQ:CPTS) 59.1%
198 IRIS International, Inc. (NASDAQ:IRIS) 59.0%
199 NovaMed, Inc. (NASDAQ:NOVA) 58.8%
200 Eurand N.V. (NASDAQ:EURX) 58.8%
201 Exactech, Inc. (NASDAQ:EXAC) 58.4%
202 Accretive Health, Inc. (NYSE:AH) 58.4%
203 AMN Healthcare Services, Inc. (NYSE:AHS) 58.4%
204 Palomar Medical Technologies, Inc. (NASDAQ:PMTI) 58.2%
205 HearUSA, Inc. (AMEX:EAR) 57.9%
206 Targacept , Inc. (NASDAQ:TRGT) 57.9%
207 OraSure Technologies, Inc. (NASDAQ:OSUR) 57.0%
208 Capital Senior Living Corporation (NYSE:CSU) 56.9%
209 Ardea Biosciences, Inc. (NASDAQ:RDEA) 56.8%
210 MAP Pharmaceuticals Inc. (NASDAQ:MAPP) 56.7%
211 Gentiva Health Services, Inc. (NASDAQ:GTIV) 56.3%
212 Healthways, Inc. (NASDAQ:HWAY) 55.6%
213 Prestige Brands Holdings, Inc. (NYSE:PBH) 55.3%
214 Penwest Pharmaceuticals (NASDAQ:PPCO) 55.3%
215 Jazz Pharmaceuticals, Inc. (NASDAQ:JAZZ) 55.2%
216 Response Genetics, Inc. (NASDAQ:RGDX) 55.1%
217 Kindred Healthcare, Inc. (NYSE:KND) 55.0%
218 Omeros Corporation (NASDAQ:OMER) 53.8%
219 ZOLL Medical Corporation (NASDAQ:ZOLL) 53.2%
220 Rochester Medical Corporation (NASDAQ:ROCM) 53.2%
221 Cantel Medical Corp. (NYSE:CMN) 52.9%
222 MELA Sciences, Inc. (NASDAQ:MELA) 52.8%
223 Tenet Healthcare Corporation (NYSE:THC) 52.8%
224 American Dental Partners, Inc. (NASDAQ:ADPI) 52.2%
225 Rexahn Pharmaceuticals, Inc. (AMEX:RNN) 52.1%
226 Transcend Services, Inc. (NASDAQ:TRCR) 51.8%
227 Almost Family, Inc. (NASDAQ:AFAM) 51.6%
228 Pharmasset, Inc. (NASDAQ:VRUS) 51.6%
229 Sinovac Biotech Ltd. (NASDAQ:SVA) 50.9%
230 VirtualScopics, Inc. (NASDAQ:VSCP) 50.9%
231 Adeona Pharmaceuticals, Inc. (AMEX:AEN) 50.5%
232 IsoRay, Inc. (AMEX:ISR) 50.4%
233 Community Health Systems (NYSE:CYH) 50.1%
234 NuVasive, Inc. (NASDAQ:NUVA) 49.8%
235 EDAP TMS S.A. (ADR) (NASDAQ:EDAP) 49.8%
236 Human Genome Sciences (NASDAQ:HGSI) 49.0%
237 Aga Medical Holdings, Inc (NASDAQ:AGAM) 48.1%
238 Health Management Associates, Inc. (NYSE:HMA) 47.6%
239 NightHawk Radiology Holdings, Inc. (NASDAQ:NHWK) 47.3%
240 Sirona Dental Systems, Inc. (NASDAQ:SIRO) 47.2%
241 Amedisys, Inc. (NASDAQ:AMED) 47.1%
242 Gilead Sciences, Inc. (NASDAQ:GILD) 46.3%
243 Sun Healthcare Group, Inc. (NASDAQ:SUNH) 46.2%
244 Abaxis, Inc. (NASDAQ:ABAX) 45.9%
245 Questcor Pharmaceuticals, Inc. (NASDAQ:QCOR) 45.8%
246 Codexis, Inc. (NASDAQ:CDXS) 45.5%
247 TomoTherapy Incorporated (NASDAQ:TOMO) 45.2%
248 ImmunoGen, Inc. (NASDAQ:IMGN) 45.1%
249 Medivation, Inc. (NASDAQ:MDVN) 45.1%
250 Bruker Corporation (NASDAQ:BRKR) 44.6%
251 Theravance, Inc. (NASDAQ:THRX) 44.2%
252 Auxilium Pharmaceuticals, Inc. (NASDAQ:AUXL) 44.1%
253 Orthofix International NV (NASDAQ:OFIX) 43.6%
254 Myriad Genetics, Inc. (NASDAQ:MYGN) 43.5%
255 Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) 42.9%
256 QLT Inc. (USA) (NASDAQ:QLTI) 42.9%
257 Given Imaging Ltd. (NASDAQ:GIVN) 42.8%
258 Nektar Therapeutics (NASDAQ:NKTR) 42.7%
259 Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX) 42.6%
260 IPC The Hospitalist Company, Inc. (NASDAQ:IPCM) 42.3%
261 Cepheid (NASDAQ:CPHD) 42.3%
262 CryoLife, Inc. (NYSE:CRY) 41.8%
263 Quidel Corporation (NASDAQ:QDEL) 41.2%
264 Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) 41.2%
265 Incyte Corporation (NASDAQ:INCY) 40.8%
266 Align Technology, Inc. (NASDAQ:ALGN) 40.5%
267 Wright Medical Group, Inc. (NASDAQ:WMGI) 39.9%
268 Invacare Corporation (NYSE:IVC) 39.6%
269 China Medical Technologies, Inc. (ADR) (NASDAQ:CMED) 39.6%
270 Bio-Rad Laboratories, Inc. (NYSE:BIO) 39.4%
271 Masimo Corporation (NASDAQ:MASI) 39.4%
272 Pfizer Inc. (NYSE:PFE) 38.7%
273 Elan Corporation, plc (ADR) (NYSE:ELN) 38.2%
274 Warner Chilcott Plc (NASDAQ:WCRX) 38.0%
275 United Therapeutics Corporation (NASDAQ:UTHR) 37.9%
276 Hi-Tech Pharmacal Co. (NASDAQ:HITK) 37.8%
277 Sanofi-Aventis SA (ADR) (NYSE:SNY) 36.8%
278 Crucell N.V. (ADR) (NASDAQ:CRXL) 36.4%
279 Aoxing Pharmaceutical Company, Inc. (AMEX:AXN) 36.1%
280 King Pharmaceuticals, Inc. (NYSE:KG) 35.7%
281 Metropolitan Health Networks, Inc. (AMEX:MDF) 35.4%
282 HEALTHSOUTH Corp. (NYSE:HLS) 35.1%
283 Integra LifeSciences Holdings Corp. (NASDAQ:IART) 34.4%
284 Covidien plc (NYSE:COV) 34.4%
285 Celgene Corporation (NASDAQ:CELG) 34.4%
286 Medco Health Solutions Inc. (NYSE:MHS) 34.4%
287 Mednax Inc. (NYSE:MD) 34.3%
288 Synovis Life Technologies, Inc. (NASDAQ:SYNO) 34.2%
289 Synta Pharmaceuticals Corp. (NASDAQ:SNTA) 34.1%
290 Emergency Medical Services Corporation (NYSE:EMS) 33.9%
291 Cutera, Inc. (NASDAQ:CUTR) 33.9%
292 PerkinElmer, Inc. (NYSE:PKI) 33.9%
293 Hologic, Inc. (NASDAQ:HOLX) 33.7%
294 Res-Care, Inc. (NASDAQ:RSCR) 33.5%
295 Assisted Living Concepts, Inc. (NYSE:ALC) 33.5%
296 Myrexis, Inc. (NASDAQ:MYRX) 33.3%
297 ArthroCare Corporation (NASDAQ:ARTC) 33.3%
298 SonoSite, Inc. (NASDAQ:SONO) 33.0%
299 DENTSPLY International Inc. (NASDAQ:XRAY) 32.5%
300 Griffon Corporation (NYSE:GFF) 32.5%
301 Team Health Holdings LLC (NYSE:TMH) 32.1%
302 Affymetrix, Inc. (NASDAQ:AFFX) 32.0%
303 Mindray Medical International Limited (NYSE:MR) 31.6%
304 Akorn, Inc. (NASDAQ:AKRX) 31.6%
305 Clarient, Inc. (NASDAQ:CLRT) 31.6%
306 America Service Group Inc. (NASDAQ:ASGR) 31.1%
307 Trinity Biotech plc (ADR) (NASDAQ:TRIB) 30.9%
308 LifePoint Hospitals, Inc. (NASDAQ:LPNT) 30.7%
309 Mylan Inc. (NASDAQ:MYL) 30.5%
310 Neurocrine Biosciences, Inc. (NASDAQ:NBIX) 30.2%
311 Medifast, Inc. (NYSE:MED) 29.6%
312 Amylin Pharmaceuticals, Inc. (NASDAQ:AMLN) 29.6%
313 BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) 29.4%
314 Impax Laboratories, Inc. (NASDAQ:IPXL) 29.4%
315 Lincare Holdings Inc. (NASDAQ:LNCR) 29.3%
316 WellCare Health Plans, Inc. (NYSE:WCG) 29.2%
317 Martek Biosciences Corp. (NASDAQ:MATK) 29.2%
318 Novartis AG (ADR) (NYSE:NVS) 29.2%
319 Endologix, Inc. (NASDAQ:ELGX) 29.0%
320 Coventry Health Care, Inc. (NYSE:CVH) 29.0%
321 Express Scripts, Inc. (NASDAQ:ESRX) 28.8%
322 Teleflex Incorporated (NYSE:TFX) 28.7%
323 Savient Pharmaceuticals, Inc. (NASDAQ:SVNT) 28.7%
324 Osteotech, Inc. (NASDAQ:OSTE) 28.6%
325 Abbott Laboratories (NYSE:ABT) 28.3%
326 Obagi Medical Products, Inc. (NASDAQ:OMPI) 28.2%
327 iCAD, INC. (NASDAQ:ICAD) 28.2%
328 Medical Action Industries (NASDAQ:MDCI) 28.1%
329 Baxter International Inc. (NYSE:BAX) 28.1%
330 Steris Corporation (NYSE:STE) 28.0%
331 PSS World Medical, Inc. (NASDAQ:PSSI) 28.0%
332 Patterson Companies, Inc. (NASDAQ:PDCO) 27.9%
333 Magellan Health Services, Inc. (NASDAQ:MGLN) 27.8%
334 PDL BioPharma Inc. (NASDAQ:PDLI) 27.8%
335 Life Technologies Corp. (NASDAQ:LIFE) 27.5%
336 Kensey Nash Corporation (NASDAQ:KNSY) 27.5%
337 Reliv International, Inc (NASDAQ:RELV) 27.1%
338 Idenix Pharmaceuticals, Inc. (NASDAQ:IDIX) 27.1%
339 Amgen, Inc. (NASDAQ:AMGN) 27.0%
340 U.S. Physical Therapy, Inc. (NASDAQ:USPH) 27.0%
341 Aetna Inc. (NYSE:AET) 27.0%
342 CARDIOME PHARMA CORP (NASDAQ:CRME) 26.9%
343 Catalyst Health Solutions, Inc. (NASDAQ:CHSI) 26.9%
344 Merit Medical Systems, Inc. (NASDAQ:MMSI) 26.9%
345 Universal Health Services, Inc. (NYSE:UHS) 26.6%
346 Kinetic Concepts, Inc. (NYSE:KCI) 26.6%
347 Schiff Nutrition International Inc. (NYSE:WNI) 26.3%
348 Teva Pharmaceutical Industries Ltd (ADR) (NASDAQ:TEVA) 26.1%
349 Medtronic, Inc. (NYSE:MDT) 25.8%
350 The Medicines Company (NASDAQ:MDCO) 25.7%
351 Omnicare, Inc. (NYSE:OCR) 25.3%
352 Henry Schein, Inc. (NASDAQ:HSIC) 25.1%
353 Hansen Medical, Inc. (NASDAQ:HNSN) 25.0%
354 Cephalon, Inc. (NASDAQ:CEPH) 24.8%
355 MAKO Surgical Corp. (NASDAQ:MAKO) 24.7%
356 Immucor, Inc. (NASDAQ:BLUD) 24.7%
357 St. Jude Medical, Inc. (NYSE:STJ) 24.3%
358 AtriCure Inc. (NASDAQ:ATRC) 24.3%
359 Quest Diagnostics Incorporated (NYSE:DGX) 24.3%
360 Emergent BioSolutions Inc. (NYSE:EBS) 24.1%
361 Insulet Corporation (NASDAQ:PODD) 23.9%
362 Thermo Fisher Scientific Inc. (NYSE:TMO) 23.8%
363 HealthStream, Inc. (NASDAQ:HSTM) 23.7%
364 Accuray Incorporated (NASDAQ:ARAY) 23.6%
365 Young Innovations, Inc. (NASDAQ:YDNT) 23.4%
366 Volcano Corporation (NASDAQ:VOLC) 23.1%
367 Cubist Pharmaceuticals, Inc. (NASDAQ:CBST) 23.0%
368 Haemonetics Corporation (NYSE:HAE) 23.0%
369 Waters Corporation (NYSE:WAT) 22.9%
370 Meridian Bioscience, Inc. (NASDAQ:VIVO) 22.8%
371 AMERIGROUP Corporation (NYSE:AGP) 22.6%
372 Hanger Orthopedic Group, Inc. (NYSE:HGR) 21.8%
373 Natus Medical, Inc. (NASDAQ:BABY) 21.7%
374 MEDTOX Scientific, Inc. (NASDAQ:MTOX) 21.6%
375 Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) 21.5%
376 Boston Scientific Corporation (NYSE:BSX) 21.4%
377 Techne Corporation (NASDAQ:TECH) 21.2%
378 Stryker Corporation (NYSE:SYK) 21.1%
379 SurModics, Inc. (NASDAQ:SRDX) 20.9%
380 Centene Corporation (NYSE:CNC) 20.7%
381 Five Star Quality Care, Inc. (AMEX:FVE) 20.7%
382 The Ensign Group, Inc. (NASDAQ:ENSG) 20.7%
383 AmSurg Corp. (NASDAQ:AMSG) 20.7%
384 Acorda Therapeutics Inc. (NASDAQ:ACOR) 20.6%
385 Zimmer Holdings, Inc. (NYSE:ZMH) 20.6%
386 Smith & Nephew plc (ADR) (NYSE:SNN) 20.5%
387 Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) 20.4%
388 Luminex Corporation (NASDAQ:LMNX) 20.0%
389 DexCom, Inc. (NASDAQ:DXCM) 19.9%
390 West Pharmaceutical Services Inc. (NYSE:WST) 19.8%
391 Bio-Reference Laboratories, Inc. (NASDAQ:BRLI) 19.8%
392 Chindex International, Inc. (NASDAQ:CHDX) 19.7%
393 DaVita Inc. (NYSE:DVA) 19.7%
394 HeartWare International Inc (NASDAQ:HTWR) 19.5%
395 GlaxoSmithKline plc (ADR) (NYSE:GSK) 19.3%
396 Genoptix, Inc. (NASDAQ:GXDX) 19.3%
397 Qiagen NV (NASDAQ:QGEN) 19.2%
398 UnitedHealth Group Inc. (NYSE:UNH) 19.2%
399 Johnson & Johnson (NYSE:JNJ) 19.0%
400 Genzyme Corporation (NASDAQ:GENZ) 18.6%
401 ICON plc (ADR) (NASDAQ:ICLR) 18.4%
402 Air Methods Corporation (NASDAQ:AIRM) 18.1%
403 Omnicell, Inc. (NASDAQ:OMCL) 17.9%
404 Vascular Solutions, Inc. (NASDAQ:VASC) 17.9%
405 Merck & Co., Inc. (NYSE:MRK) 17.7%
406 Alkermes, Inc. (NASDAQ:ALKS) 17.3%
407 Cyberonics, Inc. (NASDAQ:CYBX) 17.1%
408 Fresenius Medical Care AG & Co. (ADR) (NYSE:FMS) 16.9%
409 AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) 16.8%
410 PAREXEL International Corporation (NASDAQ:PRXL) 16.8%
411 Cerner Corporation (NASDAQ:CERN) 16.5%
412 Celera Corporation (NASDAQ:CRA) 16.3%
413 Owens & Minor, Inc. (NYSE:OMI) 16.2%
414 Symmetry Medical Inc. (NYSE:SMA) 16.1%
415 McKesson Corporation (NYSE:MCK) 16.0%
416 Senomyx Inc. (NASDAQ:SNMX) 15.9%
417 Becton, Dickinson and Co. (NYSE:BDX) 15.7%
418 Animal Health International, Inc. (NASDAQ:AHII) 15.7%
419 C.R. Bard, Inc. (NYSE:BCR) 15.6%
420 Charles River Laboratories (NYSE:CRL) 15.6%
421 Par Pharmaceutical Companies, Inc. (NYSE:PRX) 15.5%
422 Gen-Probe Incorporated (NASDAQ:GPRO) 15.5%
423 Enzon Pharmaceuticals, Inc. (NASDAQ:ENZN) 14.9%
424 Talecris Biotherapeutics Holdings Corp (NASDAQ:TLCR) 14.7%
425 Beckman Coulter, Inc. (NYSE:BEC) 14.3%
426 Salix Pharmaceuticals, Ltd. (NASDAQ:SLXP) 14.3%
427 Covance Inc. (NYSE:CVD) 14.3%
428 Forest Laboratories, Inc. (NYSE:FRX) 14.2%
429 Intuitive Surgical, Inc. (NASDAQ:ISRG) 13.9%
430 Shire Plc. (ADR) (NASDAQ:SHPGY) 13.7%
431 Hill-Rom Holdings, Inc. (NYSE:HRC) 13.5%
432 Perrigo Company (NASDAQ:PRGO) 12.8%
433 Kendle International Inc. (NASDAQ:KNDL) 12.6%
434 Illumina, Inc. (NASDAQ:ILMN) 12.6%
435 AmerisourceBergen Corp. (NYSE:ABC) 12.5%
436 Landauer, Inc. (NYSE:LDR) 12.4%
437 Health Net, Inc. (NYSE:HNT) 12.0%
438 Seattle Genetics, Inc. (NASDAQ:SGEN) 11.9%
439 Laboratory Corp. of America Holdings (NYSE:LH) 11.8%
440 Analogic Corporation (NASDAQ:ALOG) 11.8%
441 ICU Medical, Incorporated (NASDAQ:ICUI) 11.8%
442 SIGA Technologies, Inc. (NASDAQ:SIGA) 11.8%
443 Alcon, Inc. (NYSE:ACL) 11.6%
444 AngioDynamics, Inc. (NASDAQ:ANGO) 11.5%
445 3SBio Inc. (ADR) (NASDAQ:SSRX) 11.5%
446 Varian Medical Systems, Inc. (NYSE:VAR) 11.3%
447 Endo Pharmaceuticals (NASDAQ:ENDP) 11.3%
448 STAAR Surgical Company (NASDAQ:STAA) 9.6%
449 National Health Investors Inc (NYSE:NHI) 9.5%
450 Allergan, Inc. (NYSE:AGN) 9.3%
451 Watson Pharmaceuticals, Inc. (NYSE:WPI) 9.0%
452 WuXi PharmaTech (Cayman) Inc. (ADR) (NYSE:WX) 8.8%
453 Amarin Corporation plc (ADR) (NASDAQ:AMRN) 8.7%
454 BMP Sunstone Corp. (NASDAQ:BJGP) 8.7%
455 Hospira, Inc. (NYSE:HSP) 8.3%
456 IDEXX Laboratories, Inc. (NASDAQ:IDXX) 8.3%
457 The Cooper Companies, Inc. (NYSE:COO) 8.2%
458 MWI Veterinary Supply, Inc. (NASDAQ:MWIV) 8.0%
459 Thoratec Corporation (NASDAQ:THOR) 7.6%
460 Chemed Corporation (NYSE:CHE) 7.1%
461 Medicis Pharmaceutical Corporation (NYSE:MRX) 6.9%
462 Mediware Info. Systems (NASDAQ:MEDW) 6.8%
463 Senior Housing Properties Trust (NYSE:SNH) 6.2%
464 ABIOMED, Inc. (NASDAQ:ABMD) 5.9%
465 American Medical Systems Holdings, Inc. (NASDAQ:AMMD) 5.6%
466 Albany Molecular Research, Inc. (NASDAQ:AMRI) 5.5%
467 Cogdell Spencer Inc. (NYSE:CSA) 5.3%
468 ATS Medical, Inc. (NASDAQ:ATSI) 5.0%
469 ResMed Inc. (NYSE:RMD) 4.9%
470 Bristol Myers Squibb Co. (NYSE:BMY) 4.9%
471 Infinity Pharmaceuticals Inc. (NASDAQ:INFI) 4.7%
472 Biogen Idec Inc. (NASDAQ:BIIB) 3.7%
473 Universal Health Realty Income Trust (NYSE:UHT) 3.2%
474 Health Care REIT, Inc. (NYSE:HCN) 3.2%
475 Pharmaceutical Product Development, Inc. (NASDAQ:PPDI) 3.0%
476 Greatbatch Inc. (NYSE:GB) 2.7%
477 Eli Lilly & Co. (NYSE:LLY) 2.7%
478 Osiris Therapeutics, Inc. (NASDAQ:OSIR) 1.9%
479 Novo Nordisk A/S (ADR) (NYSE:NVO) 1.5%
480 Discovery Laboratories, Inc. (NASDAQ:DSCO) 1.0%
481 Micrus Endovascular Corporation (NASDAQ:MEND) 0.9%
482 BioForm Medical, Inc. (NASDAQ:BFRM) 0.6%
483 NxStage Medical, Inc. (NASDAQ:NXTM) 0.4%
484 HMS Holdings Corp. (NASDAQ:HMSY) 0.4%
485 Simcere Pharmaceutical Group (NYSE:SCR) 0.3%
486 Biovail Corporation (USA) (NYSE:BVF) 0.2%
487 Life Sciences Research, Inc. (NYSE:LSR) 0.0%
488 Neogen Corporation (NASDAQ:NEOG) -0.8%
489 Healthcare Realty Trust Incorporated (NYSE:HR) -0.8%
490 LCA-Vision Inc. (NASDAQ:LCAV) -1.2%
491 NBTY, Inc. (NYSE:NTY) -1.5%
492 Medical Properties Trust, Inc. (NYSE:MPW) -2.6%
493 Valeant Pharmaceuticals International (NYSE:VRX) -3.9%
494 Edwards Lifesciences Corp (NYSE:EW) -4.7%
495 AstraZeneca plc (ADR) (NYSE:AZN) -5.2%
496 Odyssey HealthCare, Inc. (NASDAQ:ODSY) -5.3%
497 Ventas, Inc. (NYSE:VTR) -5.4%
498 Psychiatric Solutions, Inc. (NASDAQ:PSYS) -6.6%
499 Millipore Corporation (NYSE:MIL) -7.7%
500 HCP, Inc. (NYSE:HCP) -7.8%
501 Somanetics Corporation (NASDAQ:SMTS) -7.9%
502 Dr. Reddy's Laboratories Limited (ADR) (NYSE:RDY) -11.2%
503 MDS Inc. (USA) (NYSE:MDZ) -13.0%
504 Virtual Radiologic Corporation (NASDAQ:VRAD) -14.0%
505 ev3 Inc. (NASDAQ:EVVV) -14.3%
506 HealthTronics Inc. (NASDAQ:HTRN) -15.6%
507 GTx, Inc. (NASDAQ:GTXI) -16.8%
LPIH approved for AMEX listing effective tomorrow -
TAIYUAN CITY, China, July 21 /PRNewswire-Asia-FirstCall/ -- Longwei Petroleum Investment Holding Ltd. (OTC Bulletin Board: LPIH) ("Longwei" or "the Company"), a leading oil and fuel wholesaler and distributor operating in Shanxi Province, China, announced today that the Company has received approval to list its common stock on NYSE AMEX. The Company will begin trading on the Amex on July 22, 2010 under the ticker symbol LPH.
"We are excited to move to NYSE Amex and believe that this transition will bring greater value to our shareholders through increased investor visibility," Mr. Cai Yongjun, Chairman and CEO of Longwei, commented. "I can think of no better way to finish a strong fiscal year and jumpstart a new one than with this pivotal move to a senior exchange. We welcome the increased responsibility and accountability that the new listing will entail, and we see it as a validation of the trust and credibility that we have worked so hard to build with our investors. As a leading petroleum distributor in China, Longwei is strongly positioned to continue expanding its reach in the coming year. The transition to NYSE Amex enables us to increase awareness in the investment community and attract a larger, more diverse shareholder base. We would like to thank our shareholders, employees, and other stakeholders for their ongoing support as we move forward into what will undoubtedly be a record year for Longwei Petroleum."
AMLJ - AML Communications Receives $3.7 Million Order for Integrated Assemblies to Be Deployed in an Unmanned Aerial Vehicle (UAV) Program
CAMARILLO, Calif.--(BUSINESS WIRE)--AML Communications, Inc. (OTCBB:AMLJ - News), a designer, manufacturer and marketer of microelectronic assemblies for the defense industry, today announced it has received a $3.7 million order for integrated microwave assemblies to be deployed in Unmanned Aerial Vehicles, also known as UAVs.
AML has developed the assemblies exclusively for this specific UAV program and is the sole source supplier. The assemblies have been previously delivered in production quantities. Delivery is planned to commence as soon as preparations for production are completed and is scheduled at a steady pace during the twelve months thereafter.
The customer, a first tier defense prime contractor has requested that the name of the program not be disclosed.
“The UAV market represents a growth opportunity for AML. It remains the strategy of AML to identify, develop and deliver products for multi year programs. The UAV contract announced today is a part of this strategy,” said Jacob Inbar, AML’s President and CEO. “Going forward, products for a number of new programs are currently being developed or have been developed and are expected to enter the production phase.
“Pentagon reports indicate that unmanned aircraft such as Predators, Global Hawks, Shadows and Ravens fill important military needs in Iraq and Afghanistan, and are forecasted to be an important part of our nation’s military strategy for the foreseeable future,” he continued. “The fact that AML was selected as a sole source provider under this order demonstrates our reputation for high performance and outstanding quality.”
OBCI - Ocean Bio-Chem, Inc. Reports: Record Sales for 2nd Quarter and Six Months 2010
FORT LAUDERDALE, FL--(Marketwire - 07/20/10) - Ocean Bio-Chem, Inc. (NASDAQ:OBCI - News) reported today that net sales for the 2nd quarter 2010, were up approximately 29% to approximately $7,360,000 compared to $5,715,000 for the comparative quarter of 2009, an increase of $1,644,500. For the six months ended June 30th, 2010, net sales were approximately $12,558,000 compared to net sales of $9,825,000 for the comparative 2009 period, an increase of $2,732,000 or 28%.
Ocean Bio-Chem President and CEO Peter Dornau commented, "I am quite satisfied with our sales performance for both the three month and six months of 2010. The Company had record high sales revenue for the second quarter and six month periods ending June 30, 2010. Despite a slow economy the Company continues to increase sales of its products in our core marine market as well as increasing sales to newer markets and customers."
Peter Dornau continued, "In addition, sales to the Company's larger marine customers increased in the second quarter, as these customers replenished store inventory levels and purchased additional products in anticipation of an improved boating season."
22 Statistics That Prove The Middle Class Is Being Systematically Wiped Out Of Existence In America
Read more: TThe Business Insider
1. 83 percent of all U.S. stocks are in the hands of 1 percent of the people.
2. 61 percent of Americans "always or usually" live paycheck to paycheck, which was up from 49 percent in 2008 and 43 percent in 2007.
3. 66% of the income growth between 2001 and 2007 went to the top 1% of all Americans.
4. 36 percent of Americans say that they don't contribute anything to retirement savings.
5. A staggering 43 percent of Americans have less than $10,000 saved up for retirement.
6. 24% of American workers say that they have postponed their planned retirement age in the past year.
7. Over 1.4 million Americans filed for personal bankruptcy in 2009, which represented a 32 percent increase over 2008.
8. Only the top 5 percent of U.S. households have earned enough additional income to match the rise in housing costs since 1975.
9. For the first time in U.S. history, banks own a greater share of residential housing net worth in the United States than all individual Americans put together.
10. In 1950, the ratio of the average executive's paycheck to the average worker's paycheck was about 30 to 1. Since the year 2000, that ratio has exploded to between 300 to 500 to one.
11. As of 2007, the bottom 80 percent of American households held about 7% of the liquid financial assets.
12. The bottom 50 percent of income earners in the United States now collectively own less than 1 percent of the nation’s wealth.
13. Average Wall Street bonuses for 2009 were up 17 percent when compared with 2008.
14. In the United States, the average federal worker now earns 60% as much as the average worker in the private sector.
15. The top 1% of U.S. households own nearly twice as much of America's corporate wealth as they did just 15 years ago.
16. In America today, the average time needed to find a job has risen to a record 35.2 weeks.
17. More than 40% of Americans who actually are employed are now working in service jobs, which are often very low paying.
18. For the first time in U.S. history, more than 40 million Americans are on food stamps, and the U.S. Department of Agriculture projects that number will go up to 43 million Americans in 2011.
19. This is what American workers now must compete against: in China a garment worker makes approximately 86 cents an hour and in Cambodia a garment worker makes approximately 22 cents an hour.
20. Despite the financial crisis, the number of millionaires in the United States rose a whopping 16 percent to 7.8 million in 2009.
21. Approximately 21 percent of all children in the United States are living below the poverty line in 2010 - the highest rate in 20 years.
22. The top 10% of Americans now earn around 50% of our national income.
OIIM/KLAC/YHOO - 3 good tech stocks
From James Altucher (WSJ)
- 02Micro International (OIIM) does the LED lighting in the iPad. The more iPads Apple sells, the better 02Micro will do. The main thing is, 02Mirco is much smaller than Apple. So even selling a few million iPads makes an enormous difference in its ultimate revenues and profits. And the company trades as if it were a virtual bankruptcy. It trades for only two times cash. For more on 02Micro, Cody Willard had an excellent article on it over at Marketwatch.
- KLA-Tencor (KLAC). I agree with the blog Crossing Wall Street that we can expect good earnings from Intel. KLA-Tencor is a beneficiary of that. Intel recently decided to stick with KLA-Tencor for chiptesting when Nanometrics (NANO) didn’t quite pass every test. Meanwhile, Credit Suisse just upgraded them, giving them a price target of $40 (35% from here). The company trades for less than 10 times forward earnings and has an extra $800mm cash lying around.
- Yahoo (YHOO). This might seem like blasphemy to like Yahoo better for the short-term than Apple. In mid 1997, split adjusted they were roughly the same price (Yahoo was a little less at about $3 and Apple was between $4-5, accounting for all splits). Now Apple’s stock is over 250 and Yahoo is…$15. But I stand by my article from February 19 (when Yahoo was…$15) where I said Yahoo was the cheapest Internet stock. I don’t know about this quarter but I wouldn’t be surprised to see earnings spike by the end of the year thanks to Yahoo outsourcing their search to Microsoft (MSFT). This is a deal that the media didn’t seem to like but I think will be an enormous win for Yahoo in the long run.
You are not kidding. They are just better at it.
If you are believer in Buffett, good news:
Buffett: 'We’re coming back, no question in my mind'
By Willow Bay willow Bay – Thu Jul 8, 1:56 am ET
When Warren Buffett looks at America's economy, he sees recovery.
In an exclusive interview with Yahoo! News and the Huffington Post, Buffett disagreed with New York Times columnist and Nobel Prize-winning economist Paul Krugman, who wrote recently that he fears the U.S. is in “the early stages of a third depression.”
Watch Buffett’s analysis of the economy here: http://news.yahoo.com/s/yblog_upshot/20100708/bs_yblog_upshot/buffett-we--re-coming-back-no-question-in-my-mind
In the interview, Buffett says “we’re on the right course” and encourages President Obama to speak with “enormous confidence” about the country’s economic future. He says that the stimulus is working and that the economy will improve in the next two or three years.
“We’re hiring,” he adds, referring to many of his Berkshire Hathaway companies.
Buffett spoke from Sun Valley, Idaho, while attending the Allen & Company conference, an annual gathering of technology and media leaders. You can see all 12 Buffett clips on Yahoo News' Newsmakers channel.
— Anna Robertson and Erin Green produced the interview for Yahoo! News
Is this any different from what Wall Street does???? LOL...same ol game everyone plays!
RHGP - Renhuang Pharmaceuticals Receives Approval to List on the NYSE Amex
Renhuang Pharmaceuticals, Inc. (Pink Sheets: RHGP) ("Renhuang" or the "Company"), a developer, manufacturer and distributor of botanical products, bio-pharmaceuticals and traditional Chinese medicines, today announced that the Company received approval to list its common stock
on the NYSE Amex.
Renhuang expects to begin trading on the NYSE Amex on Friday, July 2, 2010. In connection with the listing on NYSE Amex, Renhuang's stock symbol will change to "CBP" from "RHGP".
"We are very pleased to move onto the NYSE Amex and begin our next phase as a public company," said Mr. Shaoming Li, Chairman of the Board, Chief Executive Officer and President of Renhuang Pharmaceuticals, Inc. "We are honored to join the family of NYSE companies
and this is an important milestone in our continuous efforts to raise our profile within the investment community, improve our stock's liquidity, expand our transparency and enhance our corporate governance."
I have not, but I do keep up with what's going on and saw the PR. The trend was down when you brought it up so I was waiting to see when it might level off. I really haven't been trading much lately.
The price is attractive, but what isn't these days. lol
Right now I'm riding out the storm. I have some low bids in patiently waiting for some good deals.
I would like to see more growth with OPXS. I know they want to expand into the international market and that would do it for me.
Good luck and I will keep an eye on it. Please let us know of any new developments.
nole
Nole, you pick up any OPXS? See the great news today? Also setting up on the weekly chart as a huge pincher.
Should go here IMO.
Penny Stock Chaser - SEC Complaint
http://www.sec.gov/litigation/complaints/2010/comp21580.pdf
I. INTRODUCTION
1. The Commission brings this emergency action to enjoin two Canadian residents from using a website they control to tout United States micro-cap companies, while at the same time clandestinely selling millions of shares of the same companies to profit from the demand they help create through their touting.
2. Starting no later than April 2009, Carol McKeown and Daniel F. Ryan, who hold themselves out as husband and wife, have used the website www.PennyStockChaser.com. to tout dozens of U.S. companies. At the same time, McKeown and Ryan have liquidated millions of shares of the same companies through their two corporations, Downshire Capital hie., and Meadow Vista Financial Corp.
3. To compensate McKeown and Ryan for the PennyStockChaser website's touting, affiliates of the touted companies ("issuers") or third parties give shares to Downshire and
Meadow Vista. Those companies then sell the shares on the open market while PennyStockChaser simultaneously predicts massive price increases for the issuers, a practice known as "scalping."
4. Furthermore, on at least two occasions, McKeown and Ryan have failed to fully disclose on PennyStockChaser the full amount of the stock they and their companies have received in exchange for the touting.
5. The Defendants have realized at least $2.4 million in net proceeds from their scalping scheme.
6. Through their conduct, McKeown, Ryan, Downshire, and Meadow Vista have violated Section 17(a) of the Securities Act of 1933 ("Securities Act") [15 U.S.C. §77q(a) and 15
U.S.C. § 77(q)(b)]; and Section l0(b) of the Securities Exchange Act of 1934 ("Exchange Act") and Exchange Act Rule l0b-5 [15 U.S.C. §78j(b) and 17 C.F.R. §240.l0b-5]. McKeown, Ryan, and Meadow Vista have also violated Section 17(b) of the Securities Act. Unless the Court enjoins them, they are reasonably likely to continue to violate these provisions.
II. DEFENDANTS
7. McKeown, 44, is a Canadian citizen residing in Montreal, Canada. She is the owner and sole officer and director of Downshire and the president and owner of Meadow Vista. She also owns the trade mark "PennyStockChaser" in the United States and Canada. She licensed the trade mark "PennyStockChaser" to Downshire. She and Ryan control PennyStockChaser.
8. Ryan also resides in Montreal. Ryan has entered into agreements on behalf of Downshire as its managing director, and has conducted trading on behalf of Downshire and Meadow Vista. He also helps control PennyStockChaser.
9. Downshire is a Quebec, Canada corporation headquartered in Montreal. It purports to be a private investment banking group. It holds the license to use the trade mark "PennyStockChaser" in the United States and Canada, whose stated services include providing a website featuring stock market information.
10. Meadow Vista is a Wyoming corporation which purports to be an investment bank headquartered in Cheyenne, Wyoming.
III. JURISDICTION AND VENUE
11. The Court has jurisdiction over this action pursuant to Sections 20(b), 20(d), and 22(a) of the Securities Act [15 U.S.C. §§77t(b), 77t(d), and 77(v)(a)]; and Sections 21(d), 21(e), and 27 of the Exchange Act [15 U.S.C. §§78u(d), 78u(e), and 78aa].
12. The Court has personal jurisdiction over the Defendants, and venue is appropriate in the Southern District of Florida. As described below, many of the transactions, acts, practices and courses of business constituting violations of the Securities Act and Exchange Act occurred in the Southern District of Florida as well as in the United States.
13. For example, Meadow Vista maintains brokerage accounts at a firm in Boca Raton, Florida, where the Defendants receive, purchase, and sell shares of the companies touted on PennyStockChaser. McKeown signed the account opening forms for these accounts, and is listed as corporation owner on them. McKeown and Ryan control and manage these brokerage accounts, including by regularly sending e-mails to brokers at the Boca Raton firm directing trading in these accounts. Downshire and Meadow Vista also maintain accounts at no fewer than three other brokerage firms in the United States, where McKeown has also signed account opening forms.
14. In addition, PennyStockChaser has touted in the last year or currently is touting the stock of Biocentric Energy Holdings, Inc. a Florida corporation; MSE Enviro-Tech Corp., a company headquartered in Miami; and Bluewave Group, Inc. a company headquartered in Fort Lauderdale. McKeown and Ryan additionally have directed PennyStockChaser's touting of at least 65 United States companies in the past year.
15. Furthermore, as described in more detail below, Ryan in 2009 entered into a written agreement with a Boca Raton-based stock broker to provide consulting services to PennyStockChaser, and solicited stock recommendations from a second Florida-based broker.
16. In connection with the conduct alleged in the Complaint, the Defendants, directly and indirectly, singly or in concert with others, have made use of the means or instrumentalities of interstate commerce,· the means or instruments of transportation and communication in interstate commerce, and the mails.
IV. THE FRAUDULENT SCHEME
A. The Defendants'Purported Business
17. Since no later than April 1,2009, McKeown, Ryan, and Downshire have owned and operated PennyStockChaser.
18. The PennyStockChaser website states it is a team of research analysts, stock brokers, investment bankers, and traders that conducts thorough research on stocks and . companies to recommend stock purchases to the investing public.
19. Through the website, McKeown, Ryan, and Downshire tout penny stocks and invite the investing public to subscribe to receive daily stock alerts through e-mail, text messages, Facebook, and Twitter.
20. In 2009 alone, McKeown, Ryan, and Downshire used the website to alert the investing public to more than 65 penny stock recommendations, and they are currently using the website to tout nine issuers.
B. The Defendants' Control Over PennyStockChaser
21. McKeown owns the PennyStockChaser website and the trade mark PENNYSTOCKCHASER. Since no later than April 14, 2009, McKeown has issued press releases concerning the stock recommendations she has had the website make. McKeown also has posted messages on Twitter concerning the stock recommendations published on PennyStockChaser.
22. Ryan controls the content of the website and has negotiated and entered into contracts on its behalf. For example, in 2009, Ryan entered into the aforementioned contract with the Boca Raton stock broker for the broker to provide consulting services to PennyStockChaser. The contract called for the broker to, among other things, provide content, stock recommendations, and market information to the website. Ryan also solicited and paid a second Florida-based broker-dealer to provide stock recommendations to publish on the website.
23. Downshire holds the license to use the trade mark PENNYSTOCKCHASER in the United States and Canada pursuant to a license agreement entered into between McKeown and Downshire.
C. The Defendants' Fraudulent Misrepresentations And Omissions
24. Directly, or by virtue of controlling PennyStockChaser, McKeown, Ryan, and Downshire have made material misrepresentations and omissions concerning their activity on PennyStockChaser.
1. The Defendants' Failure To Adequately Disclose Their Sale Of Stocks They Tout
25. As compensation for McKeown and Ryan's touting the issuers' stock, Downshire and Meadow Vista receive shares of the issuers from issuers' affiliates or third parties, then sell them on the open market. The Defendants also purchase shares of the stock they tout on PennyStockChaser and sell them for profits after their promotional campaigns increase the stock prices. McKeown and .Ryan direct and control trading in the Downshire and Meadow Vista accounts.
26. The Defendants fail to adequately disclose they are simultaneously selling shares of the stocks they tout. The PennyStockChaser website states only that it "may be selling shares of stock at the same time the profile is being disseminated to potential investors; this should be' viewed as a definite conflict of interest and as such, the reader should take this into consideration." In truth, the Defendants have regularly been selling massive quantities of the stock they tout on the website.
i. Converge Global, Inc.
27. From no later than May 11,2009 until at least June 1,2009, McKeown, Ryan, and Downshire used PennyStockChaser to promote the stock of Converge Global, Inc., a Utah corporation purportedly in the business of acquiring and developing properties whose stock is quoted on Pink OTC Markets Inc. (the "Pink Sheets") under ticker symbol "CVRG."
28. Specifically, during this time period, the website touted Converge's stock to the investing public at least four times:
a) On May 11, 2009, the website published, "[Converge] -Last @ .022 -Up 16% on Friday -Ready to Move Higher. ... [Converge] has the potential to jump 500%."
b) On May 14, 2009, the website stated, "[Converge] shares rose over 400% since our last alert. We recommended [Converge] to our members at $.022 and [Converge] closed yesterday at $.13. This was up 490%."
c) On June 1,2009, the website published, "[Converge] shares moved from our recommendation at $.02 to a high of$.044 that is a 2100% increase."
d) Later, on June 13,2009 The website touted "[Converge] IS WAY TO LOW [sic] ... [Converge] IS ON NEWS WATCH!!! [Converge] is on our watch list for a 100% -300% move."
29. Converge's stock price and trading volume increased significantly as a result of the Defendants' promotional campaign. For example, the week before the campaign began, Converge's average price per share ranged from 1.9 to 2.2 cents a share and the highest average trading volume was 311,160 shares. However, between May 11 and 29, 2009, Converge's stock price was quoted as high as almost 4 cents a share, while its volume averaged up to 16,098,530 shares per day -more than 50 times the previous volume.
30. Between May 11, 2009 and July 6, 2009 -during and after touting Converge's stock on the website -McKeown and Ryan had Downshire sell almost 6.3 million shares of Converge stock for approximately $602,000 in net proceeds.
ii. Biocentric Energy Holdings, Inc.
31. In July 2009, McKeown, Ryan, and Downshire used PennyStockChaser to promote Biocentric Energy Holdings, Inc., a Florida corporation purportedly in the business of developing green energy technology whose stock is quoted on the Pink Sheets under ticker symbol "BEHL."
32. Specifically, during this time period, the website touted Biocentric's stock to the investing public at least four times: a) On July 4,2009, the website touted, "[Biocentric] is the real deal. ... This stock already has HUGE VOLUME and it will only get better." b) On July 10,2009, the website exclaimed, "[Biocentric] is building a solid base @ .03 for lift off;" "News is coming on [Biocentric] and when it does, WATCH OUT, .1 0+ IS NEAR; and "[T]he last PR shows us that revenue is around the comer for [Biocentric]. Once revenue starts these guys could gross $30 million + per calendar year." c) On July 12,2009, the website touted, "We think [Biocentric] could move past .10 and then .20.... Members should be buying this stock @.029 and socking the stock away... THIS WILL BE A HUGE WINNER." d) On July 19,2009, the website published, "[Biocentric] should move to the .10 level on strong news."
33. Biocentric's stock price and trading volume increased significantly as a result of the Defendants' promotional campaign. During the week before the campaign began, Biocentric's stock price was quoted at less than a penny per share, and the trading volume peaked at 4.3 million shares per day. During the two weeks following the promotional campaign, Biocentric's stock price was quoted as high as 3 cents a share, and trading volume ranged from 10 million to 30 million shares per day.
34. Between July 13, 2009 and July 21, 2009, Ryan and McKeown had Downshire sell almost 24 million shares of Biocentric stock for net proceeds of$569,000.
iii. Bluewave Group, Inc.
35. From no later than April 7, 2010 through the present, the PennyStockChaser website has been touting the stock of Bluewave Group, Inc., a Nevada corporation headquartered in Fort Lauderdale, Florida, purportedly in the business of multi-media digital distribution whose securities are registered with the Commission and quoted on the Pink Sheets under ticker symbol "BLEW."
36. Specifically, during this time, the website has touted Bluewave to the investing
public at least four times, and continues to do so: a) On April 19,2010, the website touted, "[Bluewave], This story is going viral, [Bluewave] is on everyone's lips [sic], Monday morning is going to be amazing for [Bluewave]...WE are looking for a double or triple..." b) On April 20, 2010, the website touted, "[Bluewave], THE SHORTS ARE PILING IT ON, WHEN THEY COVER THIS STOCK WILL SOAR." "This short is creating an in built [sic] catalyst for a move higher." c) From May 3,2010 until now, the website has touted, "PSC knows how to pick a winner, VIVK, BLEW, and AVOE are set to rake in the big bucks next week;" and "VIVK, BLEW, and AVOE are where you want to be this week. The stage is set to make big money." d) From May 4, 2010 through the present, the website has said, "PSC wants you to make money, We are looking for hard bounces in VIVK and [BLUEWAVE]...BUYING STOCKS BEFORE THEY BOUNCE CAN MAKE
YOU QUICK TRADING PROFITS;" and "[Bluewave] closed @ .30 on Monday. We think [Bluewave] should be @ the least triple the stock price we are @ right now. PSC is still long a ton of stock and we are waiting for big news from the company."
37. Bluewave's trading volume increased significantly as a result of the Defendants' promotional campaign. Between January 1, 2010 and April 15,2010, immediately prior to the campaign, trading was almost non-existent with a total of only 57,100 shares traded.
38. By contrast, in the days following the promotional campaign, trading volume was almost two millions shares per day.
39. On March 19, 2010, a month prior to the promotional campaign, Meadow Vista received 1,000,000 shares of Bluewave. As the touting started, Meadow Vista sold 400,000 shares between Apri116, 2010 and April 19,2010 for net proceeds of approximately $184,000.
iv. Avro Energy, Inc.
40. From no later than April 20, 2010 through the present, PennyStockChaser has touted the stock of Avro Energy, Inc., a Nevada Corporation purportedly in the business of acquiring and developing oil and natural gas properties whose stock is registered with the Commission and are quoted on the Pink Sheets under ticker symbol "AVOE".
41. Specifically, the website has touted Avro at least four times and continues to do
so: a) On April 20, 2010, the website exclaimed, "PSC was a buyer today on [Avro] and we will continue to add tomorrow. PSC is looking for a short term target of .30 and a longer term (3 month)[sic] of$1.00 or more." b) From May 3,2010 until now, the website has touted, "PSC knows how to pick a winner, VNK, BLEW, and AVOE are set to rake in the big bucks next week;"
and "VIVK, BLEW, and AVOE are where you want to be this week. The stage is set to make big money." c) From May 27, 2010 until now, the website has touted, "Our April alert on [Avro] came in @ .07. Two days ago we focused our attention to [Avro] @ 0.16 and today it closed @ .26 up 3.92% on 1,069,440 in volume beating out its ten day average of 129,908;" "Members who followed our April alert on [Avro] are up on triple digit gains of 271.43%;" and "The sentiment on [Avro] is positive with the chart headed further north. Avro is up 36.84% from its 50 day moving average with a bullish intermediate outlook." d) From June 2, 2010 on, the website has stated, "[Avro], PSC just keeps nibbling. We bought 50,000 more shares [of Avro] today and we are up to 228.47% since mid April -looking for $1.00;" and "PSC kept adding shares of [Avro] today. As it stands now, PSC has over 2.2 million shares of [Avro] on the books. We like the company for continued traction to the upside."
42. Avro's stock price and trading volume increased significantly as a result of the Defendants' promotional campaign. In the two weeks prior to the campaign, Avro's highest closing price was just under a penny a share, and its highest trading volume was 42,300 shares per day. In contrast, from April 19 to 29, 2010, Avro's average daily stock price ranged from 1.5 to 3.2 cents per share, and its average trading volume reached more than 3 million shares per day.
43. On April 19,2010, the day before PennyStockChaser began touting Avro stock, MeadowVista bought 220,000 shares of Avro stock at prices of nine-tenths of a cent to 1.2 cents per share. The following day, while PennyStockChaser touted it was buying Avro stock, Meadow Vista sold the shares for almost 2 cents a share, making a profit of$16,000.
v. Atlantic Wind & Solar, Inc.
44. From no later than October 2009 through at least January 2010, the PennyStockChaser website promoted Atlantic Wind & Solar, Inc., a West Virginia corporation headquartered in Toronto, Canada purportedly in the business of developing solar energy products whose securities are quoted on the Pink Sheets under the ticker symbol "AWSL."
45. Specifically, during this time period the website touted Atlantic stock at least four times: a) On October 14, 2009, the website trumpeted, "[Atlantic] closed at $2.10 yesterday and it is poised to go into break out mode, THIS PICK IS HEADED TO $10.00." b) On October 21,2009, the website touted, "[Atlantic] ON TOP OF MOUNT OF PROFIT (sic) [Atlantic] is making loads of cash for members who are in the game...." "PSC spoke to the company today and they tell us that members should buckle in. Big news is coming at the end of this week." c) On December 2, 2009, the website said, "2010 could be the year for [Atlantic]. A move past $10 (pre-split) on news could be just around the comer" and "We think [Atlantic] is headed to $8-$10 pre-split." d) On January 5, 2010, the PSC website touted, "You cannot own too much of a good thing...THE ONLY ADVICE WE HAVE IS TO BUY [Atlantic] BEFORE THE CROWDS."
46. Atlantic's stock price and trading volume increased significantly as a result of the Defendants' promotional campaign. Atlantic's closing stock price went from 70 cents per share on July 22, 2009 to $4.84 per share on October 22, 2009. Days later, Atlantic's closing stock price decreased to $2.70 per share. Atlantic's daily trading volume also increased, ranging from 13,812 shares on July 22,2009 to more than 1 million shares on October 22,2009.
47. Between September 1, 2009 and January 27, 2010, Meadow Vista received 430,000 shares of Atlantic. It sold 360,000 shares for between $1.49 and $3.37 per share for approximately $780,600 in net proceeds.
vi. MSE Enviro-Tech Corp.
48. In October 2009, PennyStockChaser website touted MSE Enviro-Tech Corp., a Delaware corporation headquartered in Miami, Florida and purportedly in the business of developing fire suppressant technology whose securities are quoted on the Pink Sheets under the ticker symbol "MEVT."
49. Specifically, on October 22, 2009, the website touted, "[MSE] is on watch @ .50.... [MSE] had an initial breakout today and we think the move higher is underway;" "We think [MSE] will move 400% to 900%. Our long term target is $5.00;" and ''The stock could see a move to the $5.00 and make members big money if they move fast."
50. On October 23,2009, the website said, "[W]e like the upside on [MS~] and we think the stock will put some serious cash in your pocket. Now is the time to buy the stock and wait for the move we expect. The team @ PSC can see momentum carrying this stock to the $5.00 level." [emphasis in original].
51. MSE's stock price and trading volume increased significantly as a result of the Defendants' promotional campaign. The week before the touting, MSE's stock closed at prices between 35 and 38 cents per share, and the average daily trading volume was 26,600 shares per day. The same day the website began touting MSE's stock, the share price increased to a high of $1.30 and closed at 99 cents per share, with a volume of more than 1.5 million shares traded. After the touting ended, MSE's share price decreased and closed at 30 cents per share on November 3,2009.
52. From October 22, 2009 until November 12, 2009, Meadow Vista sold 533,334 shares of MSE stock for approximately $240,000.
2. Failure To Disclose Compensation For Touting Shares
53. The Defendants have also failed to disclose in some cases the full amount of the compensation they receive for touting stocks on PennyStockChaser.
54. For example, from September 2009 until January 2010, the website said PennyStockChaser had received 140,000 shares of Atlantic's stock from a third party. In reality, an Atlantic affiliate had transferred 430,000 shares of Atlantic stock to Meadow Vista in exchange for touting Atlantic's stock on the website.
55. Furthermore, the PennyStockChaser website states it received 350,000 shares of MSE's stock from a third party. In truth, an MSE affiliate transferred 483,334 shares of MSE's stock to Meadow Vista on October 21,2009 in exchange for touting MSE's stock on the website.
v. CLAIMS FOR RELIEF
COUNT I
THE DEFENDANTS VIOLATED SECTION 17(A)(l) OF THE SECURITIES ACT
56. The Commission repeats and re-alleges paragraphs 1 through 55 of its Complaint.
57. Since no later than April 2009, the Defendants, directly and indirectly, by use of the means or instruments of transportation or communication in interstate commerce and by use of the mails, in the offer or sale of securities, as described in this Complaint, have been knowingly, willfully or recklessly employing devices, schemes or artifices to defraud.
58. By reason of the foregoing, the Defendants, directly and indirectly, have violated and, unless enjoined, are reasonably likely to continue to violate, Section 17(a)(I) of the Securities Act [15 U.S.c. § 77q(a)].
COUNT II
THE DEFENDANTS VIOLATED SECTIONS 17(A)(2) AND 17(A)(3) OF THE SECURITIES ACT
59. The Commission repeats and re-alleges paragraphs 1 through 55 of its Complaint.
60. Since no later than April 2009, the Defendants, directly and indirectly, by use of the means or instruments of transportation or communication in interstate commerce and by the use of the mails, in the offer or sale of securities, have been: (a) obtaining money or property by means of untrue statements of material facts and omissions to state material facts necessary to make the statements made, in the light of the circumstances under which they were made, not misleading; or (b) engaging in transactions, practices and courses of business which are now operating and will operate as a fraud or deceit upon purchasers and prospective purchasers of such securities.
61. By reason of the foregoing, the Defendants, directly and indirectly, have violated and, unless enjoined, are reasonably likely to continue to violate, Sections 17(a)(2) and 17(a)(3) of the Securities Act [15 U.S.C. §§ 77q(a)(2) and 77q(a)(3)].
COUNT III
THE DEFENDANTS VIOLATED SECTION 17(b) OF THE SECURITIES ACT
As to McKeown, Ryan, and Meadow Vista
62. The Commission repeats and re-alleges paragraphs 1 through 55 of its Complaint.
63. Since no later than April 2009, the Defendants, by the use of the means or instruments of transportation or communication in interstate commerce or by the use of the mails, published, gave publicity to, or circulated communications that, though not purporting to offer securities for sale, described certain securities.
64. The Defendants received and were to receive consideration for such activities from or on behalf of the issuer of these securities and did not fully disclose the past or future receipt of such consideration and the amounts.
65. By reason of the foregoing, the Defendants, directly or indirectly, have violated and, unless enjoined, are reasonably likely to continue to violate, Section 17(b) of the Securities Act [15 U.S.C. § 77q(b)].
COUNT IV
THE DEFENDANTS VIOLATED SECTION IO(b) OF THE EXCHANGE ACT AND EXCHANGE ACT RULE I0b-5
66. The Commission repeats and re-alleges paragraphs 1 through 55 of its Complaint.
67. Since no later than April 2009, the Defendants, directly and indirectly, by use of the means and instrumentality of interstate commerce, and of the mails in connection with the purchase or sale of securities, have been knowingly, willfully or recklessly: (a) employing devices, schemes or artifices to defraud; (b) making untrue statements of material facts and omitting to state material facts necessary in order to make the statements made, in the light of the circumstances under which they were made, not misleading; or (c) engaging in acts, practices and courses of business which have operated, are now operating and will operate as a fraud upon the purchasers of such securities.
68. By reason of the foregoing, the Defendants, directly or indirectly, violated and, unless enjoined, are reasonably likely to continue to violate, Section 1O(b) of the Exchange Act
[15 U.S.C. § 78j(b), and Rule l0b-5, 17 C.F.R. § 240.10b-5]. RELIEF REQUESTED WHEREFORE, the Commission respectfully requests that the Court:
I. Declaratory Relief
Declare, determine, and find that the Defendants have committed the violations of the federal securities laws alleged herein.
II. Temporary Restraining Order, Preliminary Injunction and Permanent Injunction Issue a Temporary Restraining Order, a Preliminary Injunction and a Permanent Injunction, restraining and enjoining the Defendants, their officers, agents, servants, employees, attorneys, and all persons in active concert or participation with them, and each of them, from violating Sections 17(a) and 17(b) of the Securities Act and Section 1O(b) of the Exchange Act and Exchange Act Rule 10b-5.
III. Disgorgement Issue an Order directing the Defendants to disgorge all ill-gotten gams, including prejudgment interest, resulting from the acts or courses of conduct alleged in this Complaint.
IV. Penalties Issue an Order directing the Defendants to pay civil money penalties pursuant to Section 20(d) of the Securities Act, 15 U.S.C. § 77t(d), and Section 21(d) of the Exchange Act [15
U.S.C. § 78u(d)].
V. Penny Stock Bar
Issue an order barring McKeown and Ryan from participating in any offering of penny stock, pursuant to Section 20(g) of the Securities Act [15 U.S.C. § 77t(g)] and Section 21(d) of the Exchange Act [15 U.S.c. § 78u(d)] for the violations alleged herein.
VI. Repatriation of Proceeds
Issue an Order requiring the Defendants to take such steps as necessary to repatriate to the territory of the United States all funds and assets described in the Commission's Complaint in this action which are held by them or are under their direct or indirect control, and deposit such funds into the registry of the United States District Court for the Southern District of Florida, and provide the Commission and the Court a written description of the funds and assets repatriated.
VII. Further Relief
Grant such other and further relief as may be necessary and appropriate.
VIII. Retention of Jurisdiction
Further, the Commission respectfully requests that the Court retain jurisdiction over this action in order to implement and carry out the terms of all orders and -decrees that it may enter, or to entertain any suitable application or motion by the Commission for additional relief within the jurisdiction of this Court.
.
e Riggle Berlin
June 23, 2010
By:
Se .or Trial Counsel Florida Bar No. 630020 Direct Dial: (305)982-6322 E-mail: berlina@sec.gov
Christine Nestor Senior Trial Counsel Florida Bar No. 597211 Direct Dial: (305) 982-6367 E-mail: nestorc@sec.gov
Michael L. Riedlingerl Senior Counsel Florida Bar No. 0864331 Direct Dial: (305) 982-3616 Email: riedlingerm@sec.gov
Attorneys for Plaintiff
SECURITIES AND EXCHANGE COMMISSION
801 Brickell Avenue, Suite 1800
Miami, Florida 33131
Telephone: (305) 982-6300
Facsimile: (305) 536-4154
I
Penny Stock Chaser Busted by SEC
SEC Charges Two Canadians With Fraudulently Touting Penny Stocks on a Website, Facebook and Twitter
FOR IMMEDIATE RELEASE
2010-114
Washington, D.C., June 29, 2010 — The Securities and Exchange Commission announced today that it has obtained an emergency asset freeze against a Canadian couple who fraudulently touted penny stocks through their website, Facebook and Twitter. The SEC also charged two companies the couple control and obtained an asset freeze against them.
According to the SEC's complaint, the defendants profited by selling penny stocks at or around the same time that they were touting them on www.pennystockchaser.com. The website invites investors to sign up for daily stock alerts through email, text messages, Facebook and Twitter.
Additional Materials
* Litigation Release No. 21580
* SEC Complaint
The SEC alleges that since at least April 2009, Carol McKeown and Daniel F. Ryan, a couple residing in Montreal, Canada, have touted U.S. microcap companies. According to the SEC's complaint, McKeown and Ryan received millions of shares of touted companies through their two corporations, defendants Downshire Capital Inc., and Meadow Vista Financial Corp., as compensation for their touting. McKeown and Ryan sold the shares on the open market while PennyStockChaser simultaneously predicted massive price increases for the issuers, a practice known as "scalping."
picture of the them:
"As alleged in our complaint, McKeown and Ryan used all the modern methods to communicate with investors including the PennyStockChaser website, e-mail, text messages, Facebook, and Twitter yet failed to adequately communicate that their rosy predictions for touted stocks were accompanied by their sales of those very same stocks." said Eric I. Bustillo, Director of the SEC's Miami Regional Office.
The SEC's complaint, filed in the U.S. District Court for the Southern District of Florida, also alleges McKeown, Ryan and one of their corporations failed to disclose the full amount of the compensation they received for touting stocks on PennyStockChaser. The SEC alleges that McKeown, Ryan and their corporations have realized at least $2.4 million in sales proceeds from their scalping scheme.
The SEC's complaint charges McKeown, Ryan, Downshire Capital Inc. and Meadow Vista Financial Corp. with violating Section 17(a) of the Securities Act of 1933, Section 10(b) of the Securities Exchange Act of 1934, and Rule 10b-5 thereunder. The SEC's complaint also charges McKeown, Ryan and Meadow Vista Financial Corp. with violating Section 17(b) of the Securities Act of 1933. In addition to the emergency relief already granted by the U.S. District Court the Commission also seeks a preliminary injunction and permanent injunction, along with disgorgement of ill-gotten gains plus prejudgment interest and the imposition of a financial penalty, penny stock bars against the individuals and the repatriation of assets to the United States.
In the course of its investigation, the SEC worked with the Quebec Autorité des marchés financiers (AMF), which was also investigating this matter. As a result of both ongoing investigations, the AMF obtained an emergency order freezing assets and a cease trade order against McKeown, Ryan, Downshire Capital Inc. and Meadow Vista Financial Corp. The SEC appreciates the collaboration with the AMF.
The SEC's case was investigated by Michael L. Riedlinger, Timothy J. Galdencio and Eric R. Busto of the Miami Regional Office. The SEC's litigation effort will be led by Christine Nestor, Amie R. Berlin and Robert K. Levenson. The SEC's investigation is continuing.
If you like FDA plays, I would add $heff's $tation of $tocks and $olid DD to your favorites. He does a great job and has a portfolio tracker in his iBox. LINK to his board
Here's a list of October FDA plays that $heff has compiled:
Posted by: $heff Member Level Date: Wednesday, June 23, 2010 1:44:42 PM
In reply to: None Post # of 30240 Send a link via email Share on Facebook Tweet this post
Superbowl Bio/Pharma..w/ 13 Drug Approvals in October.
The best risk/reward IMO is AVNR and ALXA. They are both under $3.00 as well! AVNR has the added bonus of the SPA with the FDA. Both companies have stellar Phase III data to support their approvals.
OCTOBER APPROVALS
JNJ ($59.00)- Oct 1st Nucynta
JAV ($1.41) - Oct 3rd Dyloject
HGSI ($25.17)-Oct 4th Zalbin for hep C
ALXA ($2.95)-Oct 11th -AZ-004 for agitation in pts w/ schizophrenia & bi-polar (Stellar Phase III data in safety & efficacy)
JAZZ (8.14)- Oct 11th-JZP-6 for fibromyalgia
ALKS ($12.43)-Oct 12th-Vivitrol for opiod addiction
AMLN ($18.84)-Oct 22nd-Bydureon for diabetes
ARNA ($3.38)- Oct 22nd-Lorcaserin for obesity
PLX ($6.42)- Oct 27th-Uplyso for Gaucher's Disease
VVUS ($9.65)- Oct 28th-Qnexa for obesity (SPA w/FDA)
BMY ($25.20)- Oct 29th-Ongyza/metformin for diabetes
BIOD ($4.22)- Oct 30th- VIAject for diabetes
AVNR ($2.68)- Oct 30th- Zenvia for pseudobulbar Affect
GHII seems way undervalued...more good news out today.
GHII is likely to uplist with a modest reverse split...multi bagger upside from here regardless?? US listed china plays are thrown out babes now... like JADA.
INTT = Huge turnaround play heading for double digits IMO.
INTT swung deep into profitability of +.11 EPS last Q.
I'm expecting up to triple that next Q. Here's why:
(1) Conference call noted bookings one Q = sales the next.
Bookings end Q1 = $14 million.
Sales of $14 million = +200% YOY jump and 46.9% sequential.
(2) CC notes indicate:
"to be conservative" -- 35% material cost + 5% sales comission = 40%
"theoretically 60% of incremental revenue drops to the bottom line"
Doesn't expect SG&A to go over $4 million per Q for rest of year.
Do the math -- realistic +.33 EPS pre-tax or more.
(3) +.33 EPS annualized = $1.32 per share which is just insane for a stock price this cheap.
INTT could run wild into the double digits per share on earnings and/or pre-announcement of earnings.
$10 to $15 coming IMO and well over $20+ very possible.
(4) Here's an article forecasting +.31 EPS: http://seekingalpha.com/article/204847-intest-earnings-conference-call-confirms-positive-view
(5) 72 year old chairman has a stock trading program for his retirement that refuses to sell any shares under $8.00 per share before even a portion of them can be sold then with requirements of higher share prices for more sales:
http://finance.yahoo.com/news/inTEST-Corporation-Executive-prnews-2524294056.html?x=0&.v=1
(6) The industry itself is going absolutely nuts. What's in store for INTT for Q3 and beyond? .50 EPS quarters or a $2 annualized pace? Pick whatever fair PE ratio you can dream of and you get a massive turn from here.
Caught with Their Chips Down
A worldwide shortage of key components is squeezing bottom lines
http://www.businessweek.com/archives/2000/b3683086.arc.htm
Here is an EE Times article that indicates that Samsung may have as much as a 50% growth in IC sales this year and is spending $9.6B on semiconductor capital.
http://www.eetimes.com/news/latest/showArticle.jhtml;jsessionid=UUPFRW30GRTMRQE1GHRSKH4ATMY32JVN?articleID=225200502
Update: LEDs in short supply as market booms
http://www.eetimes.com/showArticle.jhtml;jsessionid=UUPFRW30GRTMRQE1GHRSKH4ATMY32JVN?articleID=224900102
Analog vendors turning away business
http://www.eetimes.com/showArticle.jhtml;jsessionid=UUPFRW30GRTMRQE1GHRSKH4ATMY32JVN?articleID=224700545
Here is an interesting interview on semiconductor demand:
http://www.cnbc.com/id/15840232/?video=1512561683&play=1 <~~~ Biggest fundamental jump in demand not seen since the mid-1990s!!!
Semiconductor Equipment Spending To Double In 2010
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=51130928
Pending additions to the Russell 3000 index: (the ones that have been mentioned on this board)
CRXX, OCLR, ALXA, DVAX, MILL, INO, KERX
http://www.russell.com/Indexes/membership/Reconstitution/default.asp
PVHO and IVDN
Both of these have very small market caps (around 4-5M) and could grow rapidly in the next 12 months.
PVHO (ProVision) has signed a deal today with Eastman Kodak to install their 3D kiosks into Hispanic Grocery Stores and Circle K. Kodak is hosting a kickoff party at the ESPN Zone in LA next week for the Provision launch where they will announce the signing of another retail chain customer.
IVDN (Innovative Designs) has completed testing on their new house wrap product that will compete with Tyvek. The wrap should be in production within a few months. IVDN also retails a winter clothing line and has signed a deal with Canadian Tire. The name is misleading. Canadian Tire is the superstore of Canada. Think of Target/Home Depot/Sears combo. This alone should add significant revenue.
http://www.canadiantire.ca/
HDY is IMO going to create many new millionaires. I'm a die hard long term believer in the concession and the NEW mgt. team. They will win this thing...I'll be on all "free" shares with any luck before the first well is drilled. I could sell half my stock into coming rallies and still be over weight...HDY remains my last over weight play...sort of my last bad stock market habit!! GL.
HDY looks interesting. I will have to do some DD this weekend. Thanks.
Welcome to the board.
nole
HDY
A long term fav. of mine is HDY...currently I find it hard to believe how low it's market cap remains. AMEX listed....currently holding enough cash thru calendar year end. Will drill offshore Guinea next year for oil/gas. This co. is hunting elephant fields....could be billions of barrels...EZ imo.
Anyhow... imo, HDY is well worth everyone's time for DD. The ceo spoke in London today.
JV operators will be competing for a stake in HDY's very significant concession. DANA petroleum has already gotten a piece of it...early bird pricing... $20M++ invested already.
GL,
Randy
Hey nole, found you here. Added this to my favs and will try to keep an eye on this as time allows.
Can't say enough good things about JADA! Undervalued...poised for big growth...could be a 2 year 10 bagger easy...much more long term IF they keep growing as they have, organically, no dilution.
Everyone has the same question..."have we hit bottom?"
Half say we are near, the other half say we have a ways to go.
I tend to like my glass half full, so I will say we are there or almost there. I'm even predicting a solid 2 days to end the week.
Every time I call 'uncle' the guys that really control our money loosen the noose.
Good luck.
REPR = home run biomed stock in the making IMO
1. Earnings out...
Sequentially for the Q:
Record sales +25%
Record operating income +268%
Record earnings +444% to +.01 EPS
Next Q due July 15.
I think REPR is well on its path to getting +.02/+.03 quarters in earnings
Translates to +.08/+.12 EPS annual pace, $1.00 - $2.00 potential target.
Lots of goodies in the 10K. A sample of them below.
2. Tidbits from the 10K...
http://www.otcmarkets.com/edgar/GetFilingHtml?FilingID=7290970
Price increase:
"In the past we marketed the pump priced at a discount to promote sales of tubing sets. We now market pumps at fair market value."
"During January 2010, a new subcutaneous immune globulin called Hizentra(R) with a greater concentration was approved by the FDA. We have performed significant testing of the new drug with the Freedom60 and have been approved by the drug company for use with their drug. Based on initial reactions, the new formulation appears to be an improved drug at higher concentrations, and is expected to replace the previous offerings."
"We anticipate these sales to continue to increase as the SCIG market continues to develop and as we work on new enhancements to the Freedom60 that we believe will expand this market even further. In addition, we expect many of the SCIG users will see benefit in using the Freedom60 system for other uses, such as antibiotics, chemotherapeutics and pain medications."
"We have been developing our own needle administration sets for subcutaneous immune globulin, which incorporates many enhanced features that we believe will address many of the issues faced by current offerings. Due to the introduction of Hizentra with its increased viscosity, the new needle administration sets were designed with improved flow characteristics. Our new needle set design has very low fluid resistance creating the ability for rapid administrations with improved safety. As mentioned previously, we are negotiating with FDA and plan to submit an FDA 510(k) application for the new set and updated performance features of the Freedom60."
"Additional new markets we have recently sold include schools and hospital-based respiratory centers. We are also planning mailings into those markets. In the school market, we have been informed that any school with a swimming pool is normally required to have suction equipment available. In addition, many schools are installing automatic electronic defibrillators (AED's) for which suction is mandatory in more than 50% of uses for this device."
3. REPR, being a biomedical stock, is largely unaffected by a negative economy. Their core product, the Freedom60, is the only device in his market approved by Medicare as it actually is a much cheaper alternative to anything out there and much safer.
From Medicare letter: "The Freedom60 Syringe Infusion Pump is the only allowable pump to be billed with the Subcutaneous Immune Globulin (SCIG)"
AML Communications Schedules Fourth Quarter and Fiscal 2010 Year End Earnings Release and Conference Call
June 02, 2010 13:00 UTC
AML Communications, Inc. (OTCBB:AMLJ), a producer of specialized amplifiers and integrated assemblies for the defense electronic warfare industry, will announce earnings results for its fourth quarter and the fiscal year ended March 31, 2010, before the market opens on Tuesday, June 8, 2010. Following the release, AML Communications will host a conference call on Tuesday, June 8, 2010, at 4:00 p.m. Eastern/1:00 p.m. Pacific Time to discuss the company's financial results and business outlook. The conference call will be conducted by Jacob Inbar, President and Chief Executive Officer.
The conference call dial-in number is (877) 212-8197 for domestic participants and (816) 249-4432 for international participants. The Conference ID number is 79581959. A replay of the call will be available for playback through the Company’s website, http://www.amlj.com/ir.html, after 6:00 AM Pacific Time on Wednesday, June 9, 2010.
About AML Communications
AML Communications is a designer, manufacturer, and marketer of specialized amplifiers and integrated assemblies that address the defense electronic warfare markets. Its key customers include Raytheon, Lockheed Martin, Northrop Grumman, L-3 Communications, BAE, and others. The Company’s extensive range of microwave low noise amplifiers and power amplifiers can be found in leading defense projects. For more information, visit www.amlj.com.
Forward-Looking Statements
This press release contains forward-looking statements made in reliance upon the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include, but are not limited to, the Company’s views on future profitability, commercial revenues, market growth, capital requirements, new product introductions, and are generally identified by words such as "thinks," "anticipates," "believes," "estimates," "expects," "intends," "plans," “schedules,” and similar words. Forward-looking statements are not guarantees of future performance and are inherently subject to uncertainties and other factors which could cause actual results to differ materially from the forward-looking statements. These factors and uncertainties include: reductions or cancellations in orders from new or existing customers; success in the design of new products; the opportunity for future orders from domestic and international customers including, in particular defense customers; general economic conditions; the limited number of potential customers; variability in gross margins on new products; inability to deliver products as forecast; failure to acquire new customers; continued or new deterioration of business and economic conditions in the wireless communications industry; and intensely competitive industry conditions with increasing price competition. The Company refers interested persons to its most recent Annual Report on Form 10-K and its other SEC filings for a description of additional uncertainties and factors that may affect forward-looking statements. Forward-looking statements are based on information presently available to senior management, and the Company has not assumed any duty to update its forward-looking statements.
AML Communications, Inc.
Jacob Inbar
President and Chief Executive Officer
805-388-1345, Ext. 201
NPHC-
about the New new distributor :
Henry Schein operates its four business groups - Dental, Medical, International, and Technology - through a centralized and automated distribution network, which provides customers in more than 200 countries with a comprehensive selection of more than 90,000 national and Henry Schein private-brand products in stock, as well as over 100,000 additional products available to our customers as special order items. Henry Schein offers a wide range of innovative, value-added practice solutions for healthcare professionals, such as ArubA®, the Company's electronic catalog and ordering system. Its leading practice-management software solutions have an installed user base of more than 65,000 practices and includes DENTRIX®, Easy Dental®, Oasis®, and EXACT® for dental practices; MicroMD® for physician practices; and AVImark® for animal health clinics. Headquartered in Melville, New York, Henry Schein employs more than 13,500 people, and has operations or affiliates in 23 countries. The Company's sales reached a record $6.5 billion in 2009.
Investor Relations
--------------------------------------------------------------------------------
Webcasts
6.5 Billion in Sales in 2009 with 18% yearly growth for 14 years
A Heritage of Growth Through
INNOVATIVE SOLUTIONS FOR HEALTHCARE PROFESSIONALS
Henry Schein, Inc., a FORTUNE 500® company and a member of the NASDAQ 100® Index, is the largest distributor of healthcare products and services to medical, dental, and veterinary office-based practitioners. The Company has been named "Most Admired" in its industry in FORTUNE's list of the World's "Most Admired" Companies, and number one in its industry in social responsibility for 5 out of the past 6 years.
Now more than ever, healthcare providers require specialized products and services to operate their practices efficiently. We offer an extensive selection of dental supplies, medical supplies, pharmaceuticals, vaccines, equipment, software technology, and much more. Our portfolio of practice solutions is designed to support our customers and to successfully meet their business goals and achieve optimal patient satisfaction.
Stock Quotes
Security: HSIC (Common)
$56.41 - 0.4 (0.70%)
Minimum 20 minutes delayed
Current Day's High: $56.83
Current Day's Low: $56.05
Current Day's Volume: 530,065
Last Trade: 05/28/10 4:00 p.m. ET
NOTE: The stock price performance shown on the quote above is not necessarily indicative of future price performance.
About Henry Schein
--------------------------------------------------------------------------------
Investor Relations > About Henry Schein
Henry Schein, a Fortune 500® company and a member of the NASDAQ 100® Index, is the largest provider of health care products and services to office-based practitioners. Recognized for its excellent customer service and highly competitive prices, the Company's four business groups – Dental, Medical, International and Technology – serve more than 600,000 customers worldwide, including dental practitioners and laboratories, physician practices and animal health clinics, as well as government and other institutions. Henry Schein operates through a centralized and automated distribution network, which provides customers in more than 200 countries with a comprehensive selection of more than 90,000 national and Henry Schein private-brand products in stock, as well as more than 100,000 additional products available as special-order items. Henry Schein also provides exclusive, innovative technology offerings for dental, medical and veterinary professionals, including value-added practice management software and electronic health record solutions
NPHC -Huge News
Nutra Pharma Partners With Henry Schein for Distribution of Nyloxin-Branded Pain Relievers
CORAL SPRINGS, FL -- (Marketwire)
06/01/10
Nutra Pharma Corp. (OTCBB: NPHC), a biotechnology company that is developing treatments for Adrenomyeloneuropathy (AMN), HIV and Multiple Sclerosis (MS), has announced today that it has partnered with leading healthcare products distributor, Henry Schein, for distribution of its Nyloxin-branded pain relievers in the United States.
Henry Schein, which ranks #339 on the Fortune 500 list, is the largest distributor of healthcare products and services to medical, dental, and veterinary office-based practitioners. With more than 12,500 "Team Schein Members" worldwide, the Company currently serves approximately 45% of the estimated 250,000 U.S. office-based physician practices, surgical centers and other alternate-care sites. Additionally, the Company serves approximately 85% of the estimated 136,000 U.S. and Canadian office-based dental practices, dental laboratories, as well as governments and other institutions and approximately 75% of the estimated 27,000 U.S. animal health practices.
"As one of the furthest reaching and most admired distributors of healthcare products, we are pleased to partner with Henry Schein for distribution of Nyloxin in the United States," commented Rik J Deitsch, Chairman and CEO of Nutra Pharma Corporation. "We look forward to strengthening our Nyloxin-brand by working closely with Henry Schein to support their distribution of Nyloxin," he said.
Nutra Pharma currently offers two pain relievers under the Nyloxin brand, Nyloxin OTC and Nyloxin Rx. Nyloxin OTC is the Company's over-the-counter (OTC) treatment for moderate to severe (Stage 2) chronic pain. Nyloxin Rx is the Company's prescription treatment for severe (Stage 3) chronic pain. Unlike Stage 2 pain, which interferes with both work and sleep, Nyloxin Rx is aimed at treating the most severe pain that inhibits one's ability to fully function. Both Nyloxin OTC and Nyloxin Rx are manufactured by Nutra Pharma's wholly-owned drug discovery subsidiary, ReceptoPharm, and are available as an oral spray and topical gel.
In addition, Nutra Pharma recently announced the first manufacturing release of Nyloxin Rx for marketing-related distribution. Physicians can currently request samples of Nyloxin Rx through the Healthcare Providers' section of the Nyloxin website: http://www.Nyloxin.com/healthcare_providers.
About Nutra Pharma Corp.
Nutra Pharma Corporation operates as a biotechnology company specializing in the acquisition, licensing, and commercialization of pharmaceutical products and technologies for the management of neurological disorders, cancer, autoimmune, and infectious diseases.
The company, through its subsidiaries, carries out basic drug discovery research and clinical development, and also seeks strategic licensing partnerships to reduce the risks associated with the drug development process.
Currently, Nutra Pharma offers several drug products for sale for the treatment of pain: Cobroxin, the first over-the-counter (OTC) pain reliever clinically proven to treat moderate to severe (Stage 2) chronic pain, and Nyloxin Rx, the only non-narcotic and non-addictive treatment for severe (Stage 3) pain. Both Cobroxin and Nyloxin were developed by Nutra Pharma's wholly-owned drug discovery subsidiary, ReceptoPharm.
In addition to manufacturing Cobroxin and Nyloxin, ReceptoPharm is also developing proprietary therapeutic protein products primarily for the prevention and treatment of viral and neurological diseases, including Multiple Sclerosis (MS), Adrenomyeloneuropathy (AMN), and Human Immunodeficiency Virus (HIV), and pain in humans. Outside of its role as the drug discovery arm for Nutra Pharma, ReceptoPharm provides contract research services through its ISO class 5 and GMP certified facilities.
The company's wholly-owned medical devices subsidiary, Designer Diagnostics, engages in the research and development of diagnostic test kits designed to be used for the rapid identification of infectious diseases, such as Nontuberculous Mycobacteria (NTM).
Nutra Pharma continues to identify intellectual property and companies in the biotechnology arena as potential acquisition candidates.
http://www.NutraPharma.com
http://www.Nyloxin.com
This board is to discuss and track our stock club picks. We focus on micro-cap stocks with multi-bagger potential. Invest at your own risk.
Disclaimer: The information on this board is not a recommendation to buy or sell any stock mentioned, discussed, or featured but simply comments being shared by myself and other posters. Any decision to buy or sell should only be done after consulting with your personal investment professional.
Stock Tracker - updated 02/15/2011 8:00am | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Last update of that terrible year. China stocks killed me. I regrouped mid-year and so far so good with my 5 star growth stocks. Too bad I'm still deep in China. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Gain($) based on $1,000 initial investment. Removed: CSOL 4/1/10 - bought $0.31, sold $0.28 (finances for 2008 and 2009 have to be redone) 4/16/10 - UPDATE: accounting errors corrected/back on list at .35 open ISCR 4/12/10 - bought $0.105 3/23/10, sold $0.105 4/12/10 (no increase in income/most of 2009 income due to debt credit) |
5 Star Growth Stock Radar - Started June 25th, 2010 - Last updated 2/7/2011
(AMPH bought out in Sept 2010 at $32.50. 26% increase over June 25th PPS)
RUK | 37.04000137.04 | Feb 15 | -0.299999 0.30 | 4161041,610 | 1 | 37.040001$37.04 | -0.299999$-0.30 | -0.803426$-0.80% | 30.02 | 7.020001 $7.02 | 23.384413 23.38% | Reed Elsevier NV PLC New ADS | 32,106 | 25.03 | 11101814274.40643311.10B | Do you want to remove the symbol RUK? |
PRIM | 8.8100008.81 | Feb 15 | 0.150001 0.15 | 5975459,754 | 1 | 8.810000$8.81 | 0.150001$+0.15 | 1.732108$1.73% | 6.98 | 1.830000 $1.83 | 26.217771 26.22% | Primoris Services Corporation | 79,292 | 15.35 | 420703950.037956420.70M | Do you want to remove the symbol PRIM? |
PRGN | 3.1400003.14 | Feb 15 | -0.010000 0.01 | 339884339,884 | 1 | 3.140000$3.14 | -0.010000$-0.01 | -0.317460$-0.32% | 3.89 | -0.750000 $0.75 | -19.280203 19.28% | Paragon Shipping Inc. Class A C | 525,527 | 4.87 | 165600465.532541165.60M | Do you want to remove the symbol PRGN? |
GLT | 11.59000011.59 | Feb 15 | -0.220000 0.22 | 347625347,625 | 1 | 11.590000$11.59 | -0.220000$-0.22 | -1.862830$-1.86% | 11.28 | 0.310000 $0.31 | 2.748228 2.75% | Glatfelter Common Stock | 210,580 | 6.25 | 531505816.997528531.51M | Do you want to remove the symbol GLT? |
SIM | 8.3800008.38 | Feb 15 | 0.030000 0.03 | 5108451,084 | 1 | 8.380000$8.38 | 0.030000$+0.03 | 0.359278$0.36% | 7.55 | 0.830000 $0.83 | 10.993379 10.99% | Grupo Simec, S.A.B. de C.V. Ame | 42,956 | - | 1390267158.9860921.39B | Do you want to remove the symbol SIM? |
MDF | 4.8900004.89 | Feb 15 | 0.070000 0.07 | 146129146,129 | 1 | 4.890000$4.89 | 0.070000$+0.07 | 1.452276$1.45% | 3.99 | 0.900000 $0.90 | 22.556388 22.56% | Metropolitan Health Networks, I | 158,824 | 8.32 | 197790714.599609197.79M | Do you want to remove the symbol MDF? |
FHCO | 4.9900004.99 | Feb 15 | -0.010000 0.01 | 3949339,493 | 1 | 4.990000$4.99 | -0.010000$-0.01 | -0.200005$-0.20% | 5.56 | -0.570000 $0.57 | -10.251803 10.25% | Female Health Company (The) | 0 | 21.14 | 137175093.708038137.18M | Do you want to remove the symbol FHCO? |
TNDM | 18.09000018.09 | Feb 15 | -0.260000 0.26 | 632168632,168 | 1 | 18.090000$18.09 | -0.260000$-0.26 | -1.416895$-1.42% | 11.77 | 6.320000 $6.32 | 53.695838 53.70% | Neutral Tandem, Inc. | 368,094 | 16.45 | 599104625.053406599.10M | Do you want to remove the symbol TNDM? |
KAZ | 1.0400001.04 | Feb 15 | -0.060000 0.06 | 537463537,463 | 1 | 1.040000$1.04 | -0.060000$-0.06 | -5.454551$-5.45% | 0.72 | 0.320000 $0.32 | 44.444439 44.44% | BMB Munai, Inc. Common Stock | 259,789 | 10.30 | 53913598.02246153.91M | Do you want to remove the symbol KAZ? |
HWKN | 38.66000038.66 | Feb 15 | -0.250000 0.25 | 2044720,447 | 1 | 38.660000$38.66 | -0.250000$-0.25 | -0.642508$-0.64% | 25.39 | 13.270000 $13.27 | 52.264671 52.26% | Hawkins, Inc. | 53,280 | 16.66 | 398777898.426056398.78M | Do you want to remove the symbol HWKN? |
VIT | 33.63000133.63 | Feb 15 | -0.660000-0.66 | 416862416,862 | 1 | 33.630001$33.63 | -0.660000$-0.66 | -1.924759$-1.92% | 24.17 | 9.460001$9.46 | 39.13943339.14% | Vanceinfo Technologies Inc Amer | 559,875 | 51.03 | 1498418327.5909421.50B | Do you want to remove the symbol VIT? |
LINC | 15.58000015.58 | Feb 15 | -0.350000 0.35 | 339125339,125 | 1 | 15.580000$15.58 | -0.350000$-0.35 | -2.197115$-2.20% | 20.96 | -5.380000 $5.38 | -25.667939 25.67% | Lincoln Educational Services Co | 325,412 | 5.94 | 345533238.307953345.53M | Do you want to remove the symbol LINC? |
UVV | 41.33000241.33 | Feb 15 | -0.039997 0.04 | 190574190,574 | 1 | 41.330002$41.33 | -0.039997$-0.04 | -0.096681$-0.10% | 39.41 | 1.920002 $1.92 | 4.871865 4.87% | Universal Corporation Common St | 304,514 | 8.12 | 983364733.566284983.36M | Do you want to remove the symbol UVV? |
CKSW | 8.0800008.08 | Feb 15 | 0.230000 0.23 | 424837424,837 | 1 | 8.080000$8.08 | 0.230000$+0.23 | 2.929937$2.93% | 5.64 | 2.440000 $2.44 | 43.262410 43.26% | ClickSoftware Technologies Ltd. | 198,275 | 23.15 | 246044077.676773246.04M | Do you want to remove the symbol CKSW? |
GIVN | 19.17000019.17 | Feb 15 | 0.379999 0.38 | 193055193,055 | 1 | 19.170000$19.17 | 0.379999$+0.38 | 2.022348$2.02% | 16.65 | 2.520000 $2.52 | 15.135136 15.14% | Given Imaging Ltd. | 59,239 | 55.40 | 570959282.272339570.96M | Do you want to remove the symbol GIVN? |
DWA | 28.79999928.80 | Feb 15 | -0.760000 0.76 | 16734891,673,489 | 1 | 28.799999$28.80 | -0.760000$-0.76 | -2.571043$-2.57% | 29.74 | -0.940001 $0.94 | -3.160729 3.16% | Dreamworks Animation SKG, Inc. | 627,053 | 19.46 | 2426659135.7154852.43B | Do you want to remove the symbol DWA? |
EBIX | 24.76000024.76 | Feb 15 | -0.559999 0.56 | 493261493,261 | 1 | 24.760000$24.76 | -0.559999$-0.56 | -2.211688$-2.21% | 15.77 | 8.990000 $8.99 | 57.006977 57.01% | Ebix Inc | 501,231 | 17.62 | 861202327.960968861.20M | Do you want to remove the symbol EBIX? |
SUMR | 7.0600007.06 | Feb 15 | -0.040000 0.04 | 131780131,780 | 1 | 7.060000$7.06 | -0.040000$-0.04 | -0.563380$-0.56% | 6.78 | 0.280000 $0.28 | 4.129793 4.13% | Summer Infant, Inc. | 115,997 | 15.02 | 108985219.116688108.99M | Do you want to remove the symbol SUMR? |
CEU | 2.2400002.24 | Feb 15 | -0.010000 0.01 | 9508695,086 | 1 | 2.240000$2.24 | -0.010000$-0.01 | -0.444444$-0.44% | 4.23 | -1.990000 $1.99 | -47.044917 47.04% | China Education Alliance, Inc. | 0 | 3.94 | 70008960.29806170.01M | Do you want to remove the symbol CEU? |
ENI | 20.23000020.23 | Feb 15 | -0.030001 0.03 | 10042581,004,258 | 1 | 20.230000$20.23 | -0.030001$-0.03 | -0.148078$-0.15% | 20.25 | -0.020000 $0.02 | -0.098768 0.10% | Enersis S A Common Stock | 576,209 | 13.05 | 13185772091.63284313.19B | Do you want to remove the symbol ENI? |
CNIT | 4.5700004.57 | Feb 15 | -0.110000 0.11 | 171390171,390 | 1 | 4.570000$4.57 | -0.110000$-0.11 | -2.350420$-2.35% | 5.7 | -1.130000 $1.13 | -19.824558 19.82% | China Information Technology, I | 207,059 | 6.73 | 237891358.935833237.89M | Do you want to remove the symbol CNIT? |
ESGR | 82.51999782.52 | Feb 15 | 0.070000 0.07 | 93219,321 | 1 | 82.519997$82.52 | 0.070000$+0.07 | 0.084900$0.08% | 69.15 | 13.369997 $13.37 | 19.334775 19.33% | Enstar Group Limited | 19,039 | 8.85 | 1078123756.1416631.08B | Do you want to remove the symbol ESGR? |
TLP | 39.70999939.71 | Feb 15 | -0.090000 0.09 | 3239532,395 | 1 | 39.709999$39.71 | -0.090000$-0.09 | -0.226131$-0.23% | 30.1 | 9.609999 $9.61 | 31.926907 31.93% | Transmontaigne Partners L.P. Tr | 37,008 | 16.12 | 574087456.764221574.09M | Do you want to remove the symbol TLP? |
TAC | 21.05999921.06 | Feb 15 | 0.000000 0.00 | 2764827,648 | 1 | 21.059999$21.06 | 0.000000$+0.00 | 0.000000$0.00% | 19.77 | 1.289999 $1.29 | 6.525035 6.53% | TransAlta Corporation Ordinary | 35,606 | 19.23 | 4639517882.3471074.64B | Do you want to remove the symbol TAC? |
CNU | 4.9700004.97 | Feb 15 | 0.070000 0.07 | 280854280,854 | 1 | 4.970000$4.97 | 0.070000$+0.07 | 1.428565$1.43% | 3.63 | 1.340000 $1.34 | 36.914595 36.91% | Continucare Corp. Common Stock | 159,027 | 13.81 | 301013007.292747301.01M | Do you want to remove the symbol CNU? |
RKT | 71.45999971.46 | Feb 15 | 0.389999 0.39 | 497423497,423 | 1 | 71.459999$71.46 | 0.389999$+0.39 | 0.548754$0.55% | 51.9 | 19.559999 $19.56 | 37.687860 37.69% | Rock-Tenn Company Common Stock | 886,350 | 12.90 | 2815166663.9328002.82B | Do you want to remove the symbol RKT? |
AGU | 95.34999895.35 | Feb 15 | -2.790001 2.79 | 25181372,518,137 | 1 | 95.349998$95.35 | -2.790001$-2.79 | -2.842879$-2.84% | 50.46 | 44.889998 $44.89 | 88.961551 88.96% | Agrium Inc. Common Stock | 2,062,400 | 25.53 | 15065299758.91113315.07B | Do you want to remove the symbol AGU? |
CCJ | 43.00000043.00 | Feb 15 | -0.590000 0.59 | 21668792,166,879 | 1 | 43.000000$43.00 | -0.590000$-0.59 | -1.353522$-1.35% | 22.72 | 20.280000 $20.28 | 89.260563 89.26% | Cameco Corporation Common Stock | 2,388,120 | 18.57 | 16920199000.00000016.92B | Do you want to remove the symbol CCJ? |
ESLT | 50.68999950.69 | Feb 15 | -0.210003 0.21 | 27592,759 | 1 | 50.689999$50.69 | -0.210003$-0.21 | -0.412579$-0.41% | 52.36 | -1.670001 $1.67 | -3.189460 3.19% | Elbit Systems Ltd. | 17,202 | 11.34 | 2162992931.4002992.16B | Do you want to remove the symbol ESLT? |
PSMT | 37.34000037.34 | Feb 15 | 0.049999 0.05 | 7328073,280 | 1 | 37.340000$37.34 | 0.049999$+0.05 | 0.134082$0.13% | 24.94 | 12.400000 $12.40 | 49.719327 49.72% | PriceSmart, Inc. | 118,749 | 20.74 | 1116353984.5619201.12B | Do you want to remove the symbol PSMT? |
HOGS | 18.37999918.38 | Feb 15 | -0.270000 0.27 | 9888598,885 | 1 | 18.379999$18.38 | -0.270000$-0.27 | -1.447724$-1.45% | 13.05 | 5.329999 $5.33 | 40.842905 40.84% | Zhongpin Inc. | 228,541 | 12.39 | 647159770.450592647.16M | Do you want to remove the symbol HOGS? |
AFAM | 36.95999936.96 | Feb 15 | 0.329998 0.33 | 6590465,904 | 1 | 36.959999$36.96 | 0.329998$+0.33 | 0.900895$0.90% | 36.72 | 0.239999 $0.24 | 0.653592 0.65% | Almost Family Inc | 83,658 | 11.34 | 341510391.540527341.51M | Do you want to remove the symbol AFAM? |
JST | 10.99000010.99 | Feb 15 | 0.150100 0.15 | 3285132,851 | 1 | 10.990000$10.99 | 0.150100$+0.15 | 1.384697$1.38% | 15.95 | -4.960000 $4.96 | -31.097180 31.10% | Jinpan International Limited | 98,705 | 12.55 | 178235816.287994178.24M | Do you want to remove the symbol JST? |
DRC | 46.99000246.99 | Feb 15 | 0.100002 0.10 | 516222516,222 | 1 | 46.990002$46.99 | 0.100002$+0.10 | 0.213270$0.21% | 33 | 13.990002 $13.99 | 42.393944 42.39% | Dresser-Rand Group Inc. Common | 644,955 | 28.29 | 3784715705.1887513.78B | Do you want to remove the symbol DRC? |
ISH | 24.95999924.96 | Feb 15 | -0.220001 0.22 | 2207222,072 | 1 | 24.959999$24.96 | -0.220001$-0.22 | -0.873714$-0.87% | 22.46 | 2.499999 $2.50 | 11.130895 11.13% | International Shipholding Corpo | 27,531 | 11.77 | 141947514.793396141.95M | Do you want to remove the symbol ISH? |
FEED | 2.4300002.43 | Feb 15 | 0.040000 0.04 | 486161486,161 | 1 | 2.430000$2.43 | 0.040000$+0.04 | 1.673638$1.67% | 3.13 | -0.700000 $0.70 | -22.364215 22.36% | AgFeed Industries, Inc. | 683,891 | - | 124780503.427982124.78M | Do you want to remove the symbol FEED? |
GTIV | 26.20000126.20 | Feb 15 | -0.029999 0.03 | 285819285,819 | 1 | 26.200001$26.20 | -0.029999$-0.03 | -0.114368$-0.11% | 29.01 | -2.809999 $2.81 | -9.686312 9.69% | Gentiva Health Services, Inc. | 206,412 | 17.68 | 782725022.792816782.73M | Do you want to remove the symbol GTIV? |
IGTE | 17.90000017.90 | Feb 15 | -0.190001 0.19 | 367418367,418 | 1 | 17.900000$17.90 | -0.190001$-0.19 | -1.050307$-1.05% | 13.91 | 3.990000 $3.99 | 28.684397 28.68% | iGATE Corporation | 806,569 | 19.89 | 1010240178.4706121.01B | Do you want to remove the symbol IGTE? |
ABV | 26.77000026.77 | Feb 15 | 0.300001 0.30 | 26184562,618,456 | 1 | 26.770000$26.77 | 0.300001$+0.30 | 1.133363$1.13% | 106.17 | -79.400000 $79.40 | -74.785721 74.79% | Companhia de Bebidas das Americ | 3,063,450 | 20.58 | 83066749250.43106183.07B | Do you want to remove the symbol ABV? |
SYT | 66.01000266.01 | Feb 15 | -0.169998 0.17 | 303501303,501 | 1 | 66.010002$66.01 | -0.169998$-0.17 | -0.256872$-0.26% | 47.9 | 18.110002 $18.11 | 37.807938 37.81% | Syngenta AG Common Stock | 368,247 | 25.30 | 30719404744.14825430.72B | Do you want to remove the symbol SYT? |
VSEC | 31.45999931.46 | Feb 15 | -0.130001 0.13 | 47354,735 | 1 | 31.459999$31.46 | -0.130001$-0.13 | -0.411526$-0.41% | 37.43 | -5.970001 $5.97 | -15.949775 15.95% | VSE Corporation | 15,582 | 6.81 | 163340315.246582163.34M | Do you want to remove the symbol VSEC? |
VCO | 43.40000243.40 | Feb 15 | -0.439999 0.44 | 1458114,581 | 1 | 43.400002$43.40 | -0.439999$-0.44 | -1.003646$-1.00% | 42.01 | 1.390002 $1.39 | 3.308740 3.31% | Vina Concha Y Toro Common Stock | 2,797 | 19.04 | 1620990056.9915771.62B | Do you want to remove the symbol VCO? |
DLM | 18.94000118.94 | Feb 15 | 0.050001 0.05 | 82039848,203,984 | 1 | 18.940001$18.94 | 0.050001$+0.05 | 0.264696$0.26% | 14.76 | 4.180001 $4.18 | 28.319787 28.32% | Del Monte Foods Company Common | 6,367,180 | 14.68 | 3698091924.2763523.70B | Do you want to remove the symbol DLM? |
SF | 71.87999771.88 | Feb 15 | 5.729996 5.73 | 14790351,479,035 | 1 | 71.879997$71.88 | 5.729996$+5.73 | 8.662125$8.66% | 46.36 | 25.519997 $25.52 | 55.047449 55.05% | Stifel Financial Corporation Co | 253,435 | - | 2529313343.3532712.53B | Do you want to remove the symbol SF? |
HQS | 4.3100004.31 | Feb 15 | -0.020000 0.02 | 4727847,278 | 1 | 4.310000$4.31 | -0.020000$-0.02 | -0.461893$-0.46% | 5.5 | -1.190000 $1.19 | -21.636365 21.64% | HQ Sustainable Maritime Industr | 142,814 | 6.17 | 77127448.97604077.13M | Do you want to remove the symbol HQS? |
DAR | 14.74000014.74 | Feb 15 | -0.320001 0.32 | 11316861,131,686 | 1 | 14.740000$14.74 | -0.320001$-0.32 | -2.124838$-2.12% | 7.76 | 6.980000 $6.98 | 89.948451 89.95% | Darling International Inc. Comm | 944,784 | 28.35 | 1215489861.1259461.22B | Do you want to remove the symbol DAR? |
MR | 27.17000027.17 | Feb 15 | -0.830000 0.83 | 431976431,976 | 1 | 27.170000$27.17 | -0.830000$-0.83 | -2.964285$-2.96% | 31.98 | -4.810000 $4.81 | -15.040650 15.04% | Mindray Medical International L | 753,247 | 20.90 | 3110666138.7348183.11B | Do you want to remove the symbol MR? |
FLR | 73.30999873.31 | Feb 15 | -0.900002 0.90 | 13189631,318,963 | 1 | 73.309998$73.31 | -0.900002$-0.90 | -1.212777$-1.21% | 44.36 | 28.949998 $28.95 | 65.261491 65.26% | Fluor Corporation Common Stock | 2,122,210 | 34.13 | 13107241083.49609413.11B | Do you want to remove the symbol FLR? |
FTAR.OB | 0.9000000.90 | Feb 15 | 0.000000 0.00 | 1549515,495 | 1 | 0.900000$0.90 | 0.000000$+0.00 | 0.000000$0.00% | 0.35 | 0.550000 $0.55 | 157.142850 157.14% | FOOTSTAR INC NEW | 0 | 0.36 | 19417499.48561219.42M | Do you want to remove the symbol FTAR.OB? |
OMI | 30.48000030.48 | Feb 15 | -0.190001 0.19 | 222306222,306 | 1 | 30.480000$30.48 | -0.190001$-0.19 | -0.619500$-0.62% | 28.19 | 2.290000 $2.29 | 8.123446 8.12% | Owens & Minor, Inc. Common Stoc | 361,108 | 15.90 | 1930481251.0070801.93B | Do you want to remove the symbol OMI? |
CHL | 47.48000047.48 | Feb 15 | -0.189999 0.19 | 12094371,209,437 | 1 | 47.480000$47.48 | -0.189999$-0.19 | -0.398571$-0.40% | 50.67 | -3.190000 $3.19 | -6.295639 6.30% | China Mobile Limited Common Sto | 1,274,550 | 10.77 | 190514495243.213654190.51B | Do you want to remove the symbol CHL? |
SPR | 25.20999925.21 | Feb 15 | 0.009998 0.01 | 513799513,799 | 1 | 25.209999$25.21 | 0.009998$+0.01 | 0.039676$0.04% | 20.38 | 4.829999 $4.83 | 23.699701 23.70% | Spirit Aerosystems Holdings, In | 1,486,270 | 17.10 | 3592752599.5254523.59B | Do you want to remove the symbol SPR? |
ICLR | 22.15000022.15 | Feb 15 | -0.010000 0.01 | 149204149,204 | 1 | 22.150000$22.15 | -0.010000$-0.01 | -0.045127$-0.05% | 29.33 | -7.180000 $7.18 | -24.480056 24.48% | ICON plc | 332,550 | 14.04 | 1330639077.0835881.33B | Do you want to remove the symbol ICLR? |
ATW | 43.86999943.87 | Feb 15 | -0.540001 0.54 | 556484556,484 | 1 | 43.869999$43.87 | -0.540001$-0.54 | -1.215944$-1.22% | 25.8 | 18.069999 $18.07 | 70.038756 70.04% | Atwood Oceanics, Inc. Common St | 732,483 | 11.76 | 2835318030.9677122.84B | Do you want to remove the symbol ATW? |
TMO | 56.61999956.62 | Feb 15 | -0.530003 0.53 | 18202121,820,212 | 1 | 56.619999$56.62 | -0.530003$-0.53 | -0.927389$-0.93% | 50.9 | 5.719999 $5.72 | 11.237719 11.24% | Thermo Fisher Scientific Inc Co | 2,446,380 | 22.41 | 22279969579.69665522.28B | Do you want to remove the symbol TMO? |
CFSG | 6.1800006.18 | Feb 15 | 0.190000 0.19 | 3960539,605 | 1 | 6.180000$6.18 | 0.190000$+0.19 | 3.171954$3.17% | 9.25 | -3.070000 $3.07 | -33.189191 33.19% | China Fire & Security Group, In | 67,683 | 8.92 | 170537095.263004170.54M | Do you want to remove the symbol CFSG? |
ITC | 67.34999867.35 | Feb 15 | 0.089996 0.09 | 124410124,410 | 1 | 67.349998$67.35 | 0.089996$+0.09 | 0.133804$0.13% | 53.55 | 13.799998 $13.80 | 25.770305 25.77% | ITC Holdings Corp. Common Stock | 184,731 | 24.14 | 3411816222.7020263.41B | Do you want to remove the symbol ITC? |
STV | 6.7000006.70 | Feb 15 | -0.100000 0.10 | 6138161,381 | 1 | 6.700000$6.70 | -0.100000$-0.10 | -1.470594$-1.47% | 6.17 | 0.530000 $0.53 | 8.589948 8.59% | China Digital TV Holding Co., L | 340,628 | 12.88 | 390770788.875580390.77M | Do you want to remove the symbol STV? |
BCA | 81.82000081.82 | Feb 15 | 0.070000 0.07 | 1224712,247 | 1 | 81.820000$81.82 | 0.070000$+0.07 | 0.085627$0.09% | 49.6 | 32.220000 $32.22 | 64.959677 64.96% | Corpbanca Sponsored Reg S GDR r | 10,573 | 16.36 | 3713073406.1508183.71B | Do you want to remove the symbol BCA? |
UNF | 56.70000156.70 | Feb 15 | -0.180000 0.18 | 6125161,251 | 1 | 56.700001$56.70 | -0.180000$-0.18 | -0.316456$-0.32% | 41.84 | 14.860001 $14.86 | 35.516254 35.52% | Unifirst Corporation Common Sto | 49,219 | 14.59 | 1124701215.1336671.12B | Do you want to remove the symbol UNF? |
SID | 16.78000116.78 | Feb 15 | 0.190001 0.19 | 44338534,433,853 | 1 | 16.780001$16.78 | 0.190001$+0.19 | 1.145271$1.15% | 15.74 | 1.040001 $1.04 | 6.607374 6.61% | Companhia Siderurgica Nacional | 4,289,830 | 14.44 | 24464737601.10855124.46B | Do you want to remove the symbol SID? |
CCU | 54.70999954.71 | Feb 15 | 0.270000 0.27 | 4359643,596 | 1 | 54.709999$54.71 | 0.270000$+0.27 | 0.495960$0.50% | 44.74 | 9.969999 $9.97 | 22.284307 22.28% | Compania Cervecerias Unidas, S. | 42,742 | 15.68 | 3485026941.6809083.49B | Do you want to remove the symbol CCU? |
TTEK | 23.62000123.62 | Feb 15 | -0.349998 0.35 | 334901334,901 | 1 | 23.620001$23.62 | -0.349998$-0.35 | -1.460152$-1.46% | 20.98 | 2.640001 $2.64 | 12.583417 12.58% | Tetra Tech, Inc. | 382,833 | 19.05 | 1458771251.8310551.46B | Do you want to remove the symbol TTEK? |
DLB | 51.49000251.49 | Feb 15 | -1.230000 1.23 | 11817631,181,763 | 1 | 51.490002$51.49 | -1.230000$-1.23 | -2.333080$-2.33% | 66.46 | -14.969998 $14.97 | -22.524824 22.52% | Dolby Laboratories Common Stock | 600,161 | 19.59 | 5768682338.0470285.77B | Do you want to remove the symbol DLB? |
UGP | 61.00999861.01 | Feb 15 | 0.169998 0.17 | 5102451,024 | 1 | 61.009998$61.01 | 0.169998$+0.17 | 0.279418$0.28% | 49.17 | 11.839998 $11.84 | 24.079720 24.08% | Ultrapar Participacoes S.A. Com | 86,716 | 20.36 | 8172289275.1693738.17B | Do you want to remove the symbol UGP? |
PWR | 23.55999923.56 | Feb 15 | -0.310001 0.31 | 14795911,479,591 | 1 | 23.559999$23.56 | -0.310001$-0.31 | -1.298707$-1.30% | 21.86 | 1.699999 $1.70 | 7.776759 7.78% | Quanta Services, Inc. Common St | 2,164,070 | 29.86 | 4985343006.9923404.99B | Do you want to remove the symbol PWR? |
NPK | 125.660004125.66 | Feb 15 | -2.610001 2.61 | 1988819,888 | 1 | 125.660004$125.66 | -2.610001$-2.61 | -2.034771$-2.03% | 99.22 | 26.440004 $26.44 | 26.647857 26.65% | National Presto Industries, Inc | 25,525 | 13.68 | 862530265.136719862.53M | Do you want to remove the symbol NPK? |
NE | 39.24000239.24 | Feb 15 | -0.959999 0.96 | 57846605,784,660 | 1 | 39.240002$39.24 | -0.959999$-0.96 | -2.388057$-2.39% | 29.28 | 9.960002 $9.96 | 34.016399 34.02% | Noble Corporation New Common S | 5,576,780 | 13.01 | 9836919060.7681279.84B | Do you want to remove the symbol NE? |
SENEA | 28.75000028.75 | Feb 15 | -0.500000 0.50 | 3359333,593 | 1 | 28.750000$28.75 | -0.500000$-0.50 | -1.709402$-1.71% | 32.12 | -3.370000 $3.37 | -10.491905 10.49% | Seneca Foods Corp. | 43,516 | 13.32 | 337381250.000000337.38M | Do you want to remove the symbol SENEA? |
FLIR | 31.93000031.93 | Feb 15 | 0.010000 0.01 | 11012471,101,247 | 1 | 31.930000$31.93 | 0.010000$+0.01 | 0.031329$0.03% | 29.15 | 2.780000 $2.78 | 9.536879 9.54% | FLIR Systems, Inc. | 1,446,870 | 21.50 | 5063906468.3990485.06B | Do you want to remove the symbol FLIR? |
ASEI | 93.08000293.08 | Feb 15 | -0.599998 0.60 | 7948479,484 | 1 | 93.080002$93.08 | -0.599998$-0.60 | -0.640477$-0.64% | 73.58 | 19.500002 $19.50 | 26.501769 26.50% | American Science and Engineerin | 62,631 | 21.64 | 836416896.453857836.42M | Do you want to remove the symbol ASEI? |
EZPW | 27.45999927.46 | Feb 15 | -0.670000 0.67 | 339290339,290 | 1 | 27.459999$27.46 | -0.670000$-0.67 | -2.381799$-2.38% | 19.04 | 8.419999 $8.42 | 44.222684 44.22% | EZCORP, Inc. | 381,147 | 13.79 | 1370885534.2941281.37B |
Commission | Trade Date | Price Paid | Shrs | Holdings Value |
---|
QUICK LINKS:
Advanced Stock Screener - Stock Fetcher
REGSHO Daily Short Volume (change date in URL)
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |